



BAPATLA COLLEGE OF PHARMACY

(Sponsored by Bapatla Education Society),(Recognized by A.I.C.T.E & PCI)

(Affiliated to Jawaharlal Nehru Technological University, Kakinada)

Bapatla (Dist), Andhra Pradesh-522101

MOUs established in AY: 2020-2021

Sl.No	Name of Collaborative agency with contract details	Date of Establishment	Duration	Area of collaboration	List of Activities conducted
01	VV Institute of Pharmaceutical Sciences, Gudlavalleru, Krishna Dt, AP-521356	11/06/2020	1 year	Guest Lectures & Faculty Development Programmes	Faculty Development on 14/12/2020 and 1/02/2021
02	SIMS college of Pharmacy, Guntur-52201	11/06/2020	5 years	Guest Lectures & Faculty Development Programmes	Faculty Development on 14/12/20, 16/09/21, 21/02/2022 and 28/02/2023
03	Joginpally BR Pharmacy College(JBRPC), Amdapur X Road, Yenkapally, Moinabad, Rangareddy, Telangana State-500075	12/08/2020	5 years	Guest Lectures & Faculty Development Programmes	Faculty Development on 26/9/22, 04/10/2021 and 7/12/2020
04	NRI college of Pharmacy, pothavarappadu, Airipalli mandalam, Krishna Dt, AP-521212	16/09/2020	1 year	Guest Lectures & Faculty Development Programmes	Guest Lecture on 20/07/2021
05	National Biodiversity Authority, Taramani, Chennai-600113	07/09/2020 16/11/2020 23/11/2020	1 year	Patents Approval	Patents Approval on 30/10/2021, 17/11/2022 and 28/12/2022
06	Natco Pharma Limited, Banjarahills, Hyderabad, Telangana-500034	02/01/2021	1 year	Internships, Industrial Training & Visit	Guest lecture on 26/06/22 and author contribution of NATCO DGM for Pharmaceutical Dosage Technology book publication

T. Gubulapurushma

PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101



Bapatla College of Pharmacy

(Sponsored by The Bapatla Education Society and Affiliated to JNTU Kakinada)

BAPATLA-522101, Bapatla District (A.P.)

Office : 08643-224144, Principal:08643-221407, Email: bcp.principal@gmail.com

Dr. T.E. GOPALA KRISHNA MURTHY
Principal

MEMORANDUM OF UNDERSTANDING

Between

BAPATLA COLLEGE OF PHARMACY

&

V. V. INSTITUTE OF PHARMACEUTICAL SCIENCES

This Memorandum of Understanding (here in after called as the 'MoU') is entered into on this the 11th day of June, 2020, by and between:

BAPATLA COLLEGE OF PHARMACY, Bapatla College Rd, S.N.P. Agraharam, Bapatla, Andhra Pradesh 522101, the first Party represented herein by its Principal Dr. T. E. Gopala Krishna Murthy.

AND

V. V. INSTITUTE OF PHARMACEUTICAL SCIENCES, Gudlavalleru, Krishna Dist, Andhra Pradesh, INDIA. 521356, the second Party represented herein by its Principal Dr. A. Lakshmana Rao.

1. PURPOSE AND SCOPE

This Memorandum of Understanding (MoU) outlines the intentions of the First Party and the Second Party to engage in collaborative activities and initiatives for mutual benefit and advancement of education.



Bapatla College of Pharmacy

(Sponsored by The Bapatla Education Society and Affiliated to JNTU Kakinada)

BAPATLA-522101, Bapatla District (A.P.)

Office : 08643-224144, Principal:08643-221407, Email: bcp.principal@gmail.com

Dr. T.E. GOPALA KRISHNA MURTHY
Principal

2. AREAS OF COLLABORATION

The First Party and the Second Party agree to explore opportunities for collaboration in the following areas:

- a. Joint research projects
- b. Faculty and student exchange programs
- c. Sharing of academic resources, including course materials and publications
- d. Joint seminars, workshops, and conferences
- e. Other areas of mutual interest as identified by both parties

3. RESPONSIBILITIES OF THE PARTIES

3.1 The First Party shall:

- a. Provide necessary resources and facilities for agreed-upon activities.
- b. Designate a point of contact for coordination and communication.
- c. Share relevant expertise and knowledge for collaborative initiatives.

3.2 The Second Party shall:

- a. Contribute to the collaborative activities as agreed upon.
- b. Allocate resources and facilities as required.
- c. Appoint a point of contact for coordination and communication.



Bapatla College of Pharmacy

(Sponsored by The Bapatla Education Society and Affiliated to JNTU Kakinada)

BAPATLA-522101, Bapatla District (A.P.)

Office : 08643-224144, Principal:08643-221407, Email: bcp.principal@gmail.com

Dr. T.E. GOPALA KRISHNA MURTHY
Principal

4. DURATION

This MoU shall come into effect on the date of signing and shall remain in force for One year unless terminated earlier by mutual agreement in writing.

5. CONFIDENTIALITY

The Parties agree to treat all confidential information exchanged during the collaboration as confidential and shall not disclose it to any third party without prior written consent.

6. AMENDMENTS


Any amendments to this MoU shall be made in writing and agreed upon by both Parties.

7. TERMINATION

Either Party may terminate this MoU by providing written notice 30 days in advance. In the event of termination, ongoing collaborative activities shall be completed as agreed upon.


IN WITNESS WHEREOF, the authorized representatives of the First Party and the Second Party have executed this MoU as of the date 11th day of June, 2020.

For and behalf of
Bapatla College Of Pharmacy


Name: Dr. T. E. Gopala Krishna Murthy
Designation: Professor & Principal
Date: 11th day of June 2020

PRINCIPAL
Bapatla College of Pharmacy
Bapatla 522 101

For and behalf of
V. V. Institute of Pharmaceutical Sciences



Name: Dr. A. Lakshmana Rao
Designation: Professor & Principal
Date: 11th day of June 2020

Dr. A. Lakshmana Rao
PRINCIPAL
V. V. Institute of
Pharmaceutical Sciences
Seshadri Rao Knowledge Village
GUDLAVALLERU - 521 356.



V. V. INSTITUTE OF PHARMACEUTICAL SCIENCES

Seshadri Rao Knowledge Village, Gudlavalleru Post, A.P.





CERTIFICATE OF PARTICIPATION


This is to certify that Dr./Mr/Mrs/Miss N. Bala Krishna Associate

professor of Bapatla collage of pharmacy has participated in

One week Faculty development program on "A Future of Artificial Intelligence in Healthcare System an Advanced Data Mining Tool" held during 14-12-2020 to 19-12-2020 at V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Andhra Pradesh.


Mr. V.L. Vinod Kumar
Coordinator


Dr. A. Lakshmana
Principal


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101

V. V. INSTITUTE OF PHARMACEUTICAL SCIENCES
Seshadri Rao Knowledge Village, Gudlavalleru Post, A.P.



CERTIFICATE OF PARTICIPATION


This is to certify that Dr./Mr/Mrs/Miss Dr. V. Sree Janardhan, Associate


professor of Bapatla collage of pharmacy has participated in


One week Faculty development program on "A Future of Artificial Intelligence in Healthcare System an Advanced

Data Mining Tool" held during 14-12-2020 to 19-12-2020 at V. V. Institute of Pharmaceutical Sciences,

Gudlavalleru, Andhra Pradesh.


Mr. V.L. Vinod Kumar
Coordinator


Dr. A. Lakshmana Rao
Principal


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101



V. V. INSTITUTE OF PHARMACEUTICAL SCIENCES
Seshadri Rao Knowledge Village, Gudlavalleru Post, A.P.

CERTIFICATE OF PARTICIPATION

This is to certify that Dr./Mr/Mrs/Miss P Madhu latba Assistant
professor of Bapatla college of pharmacy has
participated in One week Faculty development program on "Gendered Contours of the Pandemic
Reinventing Public Policy and Leadership Transformation" held during 01-02-2021 to 05-02-2021 at
V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Andhra Pradesh.

M. Sai Vishnu
Mr. M. Sai Vishnu
Coordinator

T. G. Balakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101

A. Lakshmana Rao
Dr. A. Lakshmana Rao
Principal



V. V. INSTITUTE OF PHARMACEUTICAL SCIENCES
Seshadri Rao Knowledge Village, Gudlavalleru Post, A.P.

CERTIFICATE OF PARTICIPATION

This is to certify that Dr./Mr/Mrs/Miss G. Anitha Associate
professor of Bapatla collage of pharmacy has
participated in One week Faculty development program on "Gendered Contours of the Pandemic
Reinventing Public Policy and Leadership Transformation" held during 01-02-2021 to 05-02-2021 at
V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Andhra Pradesh.

M. Sai Vishnu
Mr. M. Sai Vishnu
Coordinator

T. G. Lakshman
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101

A. Lakshmana Rao
Dr. A. Lakshmana Rao
Principal

MEMORANDUM OF UNDERSTANDING

Between

SIMS COLLEGE OF PHARMACY

&

BAPATLA COLLEGE OF PHARMACY

This Memorandum of Understanding (here in after called as the 'MoU') is entered into on this the 11th of June 2020, by and between:

SIMS College of Pharmacy, Mangaladas Nagar, Guntur, Andhra Pradesh-522001, the First Party represented herein by its Principal **Dr. S.Manohar Babu**.

AND

Bapatla College of Pharmacy, Bapatla College Rd, S.N.P. Agraharam, Bapatla, Andhra Pradesh 522101, the Second Party represented herein by its Principal **Dr. T.E. Gopala Krishna Murthy**.

1. PURPOSE AND SCOPE

This Memorandum of Understanding (MoU) outlines the intentions of the First Party and the Second Party to engage in collaborative activities and initiatives for mutual benefit and advancement of education.

2. AREAS OF COLLABORATION

The First Party and the Second Party agree to explore opportunities for collaboration in the following areas:

- a. Joint research projects
- b. Faculty and student exchange programs

- c. Sharing of academic resources, including course materials and publications
- d. Joint seminars, workshops, and conferences
- e. Other areas of mutual interest as identified by both parties

3. RESPONSIBILITIES OF THE PARTIES

3.1 The First Party shall:

- a. Provide necessary resources and facilities for agreed-upon activities.
- b. Designate a point of contact for coordination and communication.
- c. Share relevant expertise and knowledge for collaborative initiatives.

3.2 The Second Party shall:

- a. Contribute to the collaborative activities as agreed upon.
- b. Allocate resources and facilities as required.
- c. Appoint a point of contact for coordination and communication.

4. DURATION

This MoU shall come into effect on the date of signing and shall remain in force for five year unless terminated earlier by mutual agreement in writing.

5. CONFIDENTIALITY

The Parties agree to treat all confidential information exchanged during the collaboration as confidential and shall not disclose it to any third party without prior written consent.

6. AMENDMENTS

Any amendments to this MoU shall be made in writing and agreed upon by both Parties.


7. TERMINATION

Either Party may terminate this MoU by providing written notice 30 days in advance. In the event of termination, ongoing collaborative activities shall be completed as agreed upon.

IN WITNESS WHEREOF, the authorized representatives of the First Party and the Second Party have executed this MoU as of the date 11th day of June 2020.

For and behalf of

SIMS College of Pharmacy



PRINCIPAL
SIMS COLLEGE OF PHARMACY
GUNTUR.




Name: **Dr. S. Manohar Babu**

Designation: Professor & Principal

Date: 11th day of June 2020

For and behalf of

Bapatla College of Pharmacy



PRINCIPAL
Bapatla College of Pharm
Bapatla 522 101



Name: **Dr. T.E. Gopala Krishna Murthy,**

Designation: Professor & Principal

Date: 11th day of June 2020

SIMS COLLEGE OF PHARMACY

MANGALDAS NAGAR, GUNTUR- 522001 ISSO 9901 : 2008 CERTIFIED INSTITUTION

APPROVED BY AICTE & PCI, NEW DELHI, INDIA

AFFILIATED BY ACHARYA NAGARJUNA UNIVERSITY



CERTIFICATE OF PARTICIPATION

This certificate is awarded to

Dr/Mr/Mrs/Miss ...*Dr. V. Sirisha... M. Pharm. Ph.D. Professor...*

of ...*Bapatla... College... of Pharmacy...* for participating in
A one week Faculty Development Program on "Revising Different Focets of
Medicinal Chemistry" held from 28.02.2023 to 04.03.2023 organised by SIMS
College of Pharmacy.

M
CONVENOR

T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101

[Signature]
PRINCIPAL



SIMS COLLEGE OF PHARMACY

MANGALDAS NAGAR, GUNTUR-522001, ISSO 9901: 2008 CERTIFIED INSTITUTION


APPROVED BY AICTE & PCI, NEW DELHI, INDIA


AFFILIATED BY ACHARYA NAGARJUNA UNIVERSITY




This is to certify that

Dr/Mr/Mrs/Miss ...Dr.M. Sathish Kumar M.pharm.php, Associate Professor...
of ...Bapatla...college...of...Pharmacy... has participated
in A One Week Faculty Development Program on "Current
Trends in Validation Methods" held from 16.09.2021 to
21.09.2021 organised by SIMS College of Pharmacy.


Convenor


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101


PRINCIPAL



SIMS COLLEGE OF PHARMACY



Mangaldas Nagar, Guntur-522001 ISSO 9901 : 2008 Certified Institution


Approved by AICTE & PCI, New Delhi, India

Affiliated by Acharya Nagarjuna University


Certificate of Participation

This is presented to

Dr/Mr/Mrs/Miss ..*Dr. V. Sri. Kishore..... M. Pharm. Ph.D. Professor.....*
of*Bapatla... College... of... Pharmacy.....* for his/her
active participation in A One Week Faculty Development
Program on Co- PO Attainment Calculation held from
21.02.2022 to 27.02.2022 organised by SIMS College of Pharmacy.


Convenor

T. G. K. Lakshmi
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101


Principal





SIMS COLLEGE OF PHARMACY



MANGALDAS NAGAR, GUNTUR-522001 ISSO 9901 : 2008 CERTIFIED INSTITUTION

APPROVED BY AICTE & PCI, NEW DELHI, INDIA


AFFILIATED BY ACHARYA NAGARJUNA UNIVERSITY


CERTIFICATE OF PARTICIPATION


Presented To

Dr/Mr/Mrs/Miss Ch. Venu babu M.pharm, Assistant professor
of Bapatla college of pharmacy for his/her

active participation in **A one week Faculty Development Program on "Assessment Strategy for OBE Mapping** held from **14.12.2020 to 19.12.2020** at SIMS College of Pharmacy.


Convenor


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101


Principal



SIMS COLLEGE OF PHARMACY



MANGALDAS NAGAR, GUNTUR-522001 ISSO 9901 : 2008 CERTIFIED INSTITUTION

APPROVED BY AICTE & PCI, NEW DELHI, INDIA

AFFILIATED BY ACHARYA NAGARJUNA UNIVERSITY


CERTIFICATE OF PARTICIPATION


Presented To


Dr/Mr/Mrs/Miss Dr. V. Sai kishore M. pharm. phD. Associate professor

of Bapatla college of pharmacy for his/her

active participation in **A one week Faculty Development Program on "Assessment Stratergy for OBE Mapping** held from **14.12.2020 to 19.12.2020** at SIMS College of Pharmacy.


Convenor


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101


Principal

MEMORANDUM OF UNDERSTANDING

Between

BAPATLA COLLEGE OF PHARMACY

and

JOGINPALLY B R PHARMACY COLLEGE (JBRPC)

This Memorandum of Understanding (hereinafter called as the 'MoU') is entered from this 12th of August 2020, by and between:

Bapatla College of Pharmacy, Bapatla College Rd, S.N.P. Agraharam, Bapatla, Andhra Pradesh 522101, which is represented by its principal herein, **Dr. T.E. Gopala Krishna Murthy** named as first party.

AND

Joginpally B R Pharmacy College (JBRPC), Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Telangana State , 500075, Telangana, India, the second party represented herein by its Principal **Dr. J V C Sharma**.

1. PURPOSE AND SCOPE

This Memorandum of Understanding (MoU) outlines the intentions of the First Party and the Second Party to engage in collaborative activities and initiatives for mutual benefit and advancement of education.

2. AREAS OF COLLABORATION

The First Party and the Second Party agree to explore opportunities for collaboration in the following areas:

- Joint research projects
- Faculty and student exchange programs
- Sharing of academic resources, including course materials and publications
- Joint seminars, workshops, and conferences
- Other areas of mutual interest as identified by both parties

3. RESPONSIBILITIES OF THE PARTIES

3.1 The First Party shall:

- Provide necessary resources and facilities for agreed-upon activities.
- Designate a point of contact for coordination and communication.
- Share relevant expertise and knowledge for collaborative initiatives.

3.2 The Second Party shall:

- Contribute to the collaborative activities as agreed upon.
- Allocate resources and facilities as required.
- Appoint a point of contact for coordination and communication.

4. DURATION

This MoU shall come into effect on the date of signing and shall remain in force for five year unless terminated earlier by mutual agreement in writing.

5. CONFIDENTIALITY

The Parties agree to treat all confidential information exchanged during the collaboration as confidential and shall not disclose it to any third party without prior written consent

6. AMENDMENTS

Any amendments to this MoU shall be made in writing and agreed upon by both Parties.


7. TERMINATION

Either Party may terminate this MoU by providing written notice 30 days in advance. In the event of termination, ongoing collaborative activities shall be completed as agreed upon.

IN WITNESS WHEREOF, the authorized representatives of the First Party and the Second Party have executed this MoU as of the date 12th of August 2020.

For and behalf of

Bapatla College of Pharmacy



Name: **Dr. T.E. Gopala Krishna Murthy.**

Designation: Professor & Principal

Date: 12th of August 2020

PRINCIPAL

**Bapatla College of Pharmacy,
Bapatla 522 101**

For and behalf of

Joginpally B R Pharmacy College (JBRPC),



Name: **Dr. JVC Sharma**

Designation: Professor & Principal

Date: 12th of August 2020

PRINCIPAL

JOGINPALLY B.R. PHARMACY COLLEGE
Yenkapally (V), Joginabad (M)
R R. Dist., Hyderabad-500 075




JBRPC


JOGINPALLY B.R. PHARMACY COLLEGE





Certificate of Participation

This is to certify that [✓]Mr./Mrs./Ms./Dr. B. Srinivasa Rao of
Bapatla College of Pharmacy has participated and
successfully completed One Week Faculty Development Program on "WRITING AND
PUBLISHING RESEARCH AND REVIEW ARTICLES" Organized by Joginpally B.R.
Pharmacy College, Moinabad, from 26th – 30th September, 2022.


Coordinator


Convener


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101


Principal





JOGINPALLY B.R. PHARMACY COLLEGE





Certificate of Participation

This is to certify that Mr./Mrs./Ms./Dr. M. Vasavi Chandrika of Bapatla College of Pharmacy has participated and successfully completed One Week Faculty Development Program on "WRITING AND PUBLISHING RESEARCH AND REVIEW ARTICLES" Organized by Joginpally B.R. Pharmacy College, Moinabad, from 26th – 30th September, 2022.


Coordinator


Convener


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101


Principal



JBRPC

JOGINPALLY B.R. PHARMACY COLLEGE



Certificate of Participation

This is to certify that Mr./Mrs./Ms./Dr. P. Snideri of
Bapatla College of Pharmacy has participated and
successfully completed One Week Faculty Development Program on "WRITING AND
PUBLISHING RESEARCH AND REVIEW ARTICLES" Organized by Joginpally B.R.
Pharmacy College, Moinabad, from 26th – 30th September, 2022.

K. Suman
Coordinator

Maheshwari
Convener

T. Gopalakrishna
Principal

T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101





JOGINPALLY B.R. PHARMACY COLLEGE





Certificate of Participation

This is to certify that ✓ Mr./Mrs./Ms./Dr. R. Venkata Krishna of Bapatla College of Pharmacy has participated and successfully completed One Week Faculty Development Program on "WRITING AND PUBLISHING RESEARCH AND REVIEW ARTICLES" Organized by Joginpally B.R. Pharmacy College, Moinabad, from 26th – 30th September, 2022.


Coordinator


Convener


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101


Principal



JBRPC

JOGINPALLY B.R. PHARMACY COLLEGE



Certificate of Participation

This is to certify that Mr./Mrs./Ms./Dr. Ch. Venu Babu of
Bapatla college of Pharmacy has participated and
successfully completed One Week Faculty Development Program on "STATISTICAL
METHODS REQUIRED FOR RESEARCH" Organized by Joginpally B.R. Pharmacy
College, Moinabad, from 04th – 08th October, 2021.

G. Lini
Coordinator

[Signature]
Convener

T. G. Balakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101

[Signature]
Principal



JOGINPALLY B.R. PHARMACY COLLEGE



Certificate of Participation

This is to certify that [✓]Mr./Mrs./Ms./Dr. B. Sudheer Choudary of
Bapatla college of Pharmacy has participated and
successfully completed One Week Faculty Development Program on "STATISTICAL
METHODS REQUIRED FOR RESEARCH" Organized by Joginpally B.R. Pharmacy
College, Moinabad, from 04th – 08th October, 2021.

Lalini
Coordinator

[Signature]
Convener

T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 104


[Signature]
Principal





JOGINPALLY B.R. PHARMACY COLLEGE

Certificate of Participation

✓
This is to certify that Mr./Mrs./Ms./Dr. K. Pohnachandra Rao of
Bapatta college of Pharmacy has participated and
successfully completed One Week Faculty Development Program on "TEACHING
METHODOLOGIES DURING AND AFTER PANDEMIC PERIOD – BUILDING e-
CONTENT" Organized by Joginpally B.R. Pharmacy College, Moinabad, from 07th – 11th
December, 2020.


Coordinator


Convener



PRINCIPAL
Bapatta College of Pharmacy
BAPATTA - 522 101
Principal





JOGINPALLY B.R. PHARMACY COLLEGE

Certificate of Participation

This is to certify that Mr./Mrs./Ms./Dr. Neelam Begum of
Bapatla college of Pharmacy has participated and
successfully completed One Week Faculty Development Program on "TEACHING
METHODOLOGIES DURING AND AFTER PANDEMIC PERIOD – BUILDING e-
CONTENT" Organized by Joginpally B.R. Pharmacy College, Moinabad, from 07th – 11th
December, 2020.


Coordinator


Convener



PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101
Principal





JOGINPALLY B.R. PHARMACY COLLEGE


Certificate of Participation

This is to certify that ✓ Mr./Mrs./Ms./Dr. K. Ranjith of
Bapatla college of Pharmacy has participated and
successfully completed One Week Faculty Development Program on "TEACHING
METHODOLOGIES DURING AND AFTER PANDEMIC PERIOD – BUILDING e-
CONTENT" Organized by Joginpally B.R. Pharmacy College, Moinabad, from 07th – 11th
December, 2020.


Coordinator


Convener


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA-522 101



Principal





JOGINPALLY B.R. PHARMACY COLLEGE


Certificate of Participation

This is to certify that Mr./Mrs./Ms./Dr. M. Poonghuzhali of
Bapatla College of Pharmacy has participated and
successfully completed One Week Faculty Development Program on "TEACHING
METHODOLOGIES DURING AND AFTER PANDEMIC PERIOD – BUILDING e-
CONTENT" Organized by Joginpally B.R. Pharmacy College, Moinabad, from 07th – 11th
December, 2020.


Coordinator


Convener


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101


Principal



Bapatla College of Pharmacy

(Sponsored by The Bapatla Education Society and Affiliated to JNTU Kakinada)

BAPATLA-522101, Bapatla District (A.P.)

Office : 08643-224144, Principal:08643-221407, Email: bcp.principal@gmail.com

Dr. T.E. GOPALA KRISHNA MURTHY
Principal

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding is (hereinafter called as the 'MOU') IS ENTERED into on this 16th day of September Two Thousand Twenty.

BY AND BETWEEN

Bapatla College of Pharmacy, Kothapalem, GBC Road, Bapatla, Guntur (Dist.), Andhra Pradesh-522101, which is represented herein by its principal Prof. & Dr. T. E. Gopala Krishna Murthy (herein after referred as First party, the Institution which expression, unless excluded by or repugnant to the subject or context shall include its successors- in office, administrators and assigns).

AND

NRI College of pharmacy, Pothavarappadu, Agiripalli Mandal, Krishna District, Andhra Pradesh-521212, Affiliated to JNTUK, KAKINADA the second Party represented herein by its principal Dr.Y.Ankamma Chowdary referred as second party.

The objectives of the MOU are:

- a. To promote and enhance academic interest between two institutions.
- b. To promote research and continuing education activities between institutions.
- c. To encourage students to participate in conference, workshops and short term courses.
- d. To utilize the expertise of senior faculty as Resource Persons.
- e. To plan a joint research and collaborative activity on mutual benefits.
- f. To facilitate usage of academic infrastructure for students and faculty members on mutual basis.

Terms and conditions:

- a. This MOU will be in force from the date up to One year it is signed by representatives of two institutions.
- b. This agreement does not involve any financial transactions between the two parties.
- c. The agreement will be in legitimacy for a period of One year from the day of signing of this agreement, until it is expressed terminated by either party on mutually agreed terms, as the case may be, will take effective steps for implementation of this MOU.
- d. Both the parties may terminate this MOU upon 30 calendar days notice in writing. In the event of termination, both parties have to discharge their obligations.

AGREED



Authorized signatory with seal

PRINCIPAL
Bapatla College of Pharmacy
Bapatla 522 101



Address of Party One:

Bapatla College of Pharmacy,
Kothapalem,
GBC Road,
Bapatla-522101
Bapatla (Dist),
Andhra Pradesh-



Authorized signatory with seal

PRINCIPAL
NRI College of Pharmacy
POTHAVARAPPADU (V)
Agiripalli (M), Krishna District

Address of Party Two:

NRI College of pharmacy,
Pothavarappadu village,
Agiripalli Mandal,
Krishna District,
Andhra Pradesh-521212

A Seminar on
Entrepreneur Developing Skills

On
20-7-21

By
Dr. T.E.G.K. Murthy, M.Pharm., Ph.D
Professor and Principal,
Bapatla College of Pharmacy, Bapatla



Organised by:
Entrepreneur Development Committee
NRICOLLEGE OF PHARMACY
Pothavarappadu (V), Agiripalli (M), Krishna District,
A.P.



National Biodiversity Authority

राष्ट्रीय जैव विविधता प्राधिकरण
(Statutory body of Ministry of Environment, Forest and Climate Change, Government of India)



J. Justin Mohan, IFS
Secretary

+91 44 2254 1071

+91 44 2254 1074

secretary@nbaa.in @ www.nbaa.org

5th Floor, CSIR Road, TICEL Bio Park,
Taramani, Chennai - 600 113, Tamil Nadu, India.

5 वां तल, सीएसआईआर रोड, टाइकल बायो पार्क,
तरामनि, चेन्नई - 600113 - तमिल नाडु, भारत

NBA/IPR Appl/3964/20 - 21/3403

24.12.2020

To

Dr. T. E. Gopala Krishnan Murthy,
Principal,
Bapatla College of Pharmacy,
Bapatla - 522 101, Guntur District,
Andhra Pradesh.

Sir,

Sub: Approval for applying for IPR as per Section 6 of the Biological Diversity Act, 2002 read with Rule 18 of the Biological Diversity Rules, 2004 - reg.

Ref: Application in Form - III received by this office on 09.03.2020.

With reference to your application cited in reference on the subject cited above to facilitate for IPR (4504/CHE/2014) on the invention titled "Statin impregnated collagen based dermal scaffolds made of cow urine" using the biological resources mentioned in the Schedule B, Annex A of the Agreement has been approved by the National Biodiversity Authority subject to the conditions laid down in the agreement.

In this regard, I am enclosing herewith one mutually signed stamp paper agreement executed between National Biodiversity Authority and the applicant for the applicant's reference and compliance. It is also to inform you that breach of the terms of agreement and provisions of the Biological Diversity Act, 2002 and Biological Diversity Rules, 2004 made thereunder will invite imposition of penalties as per Section 55, 56 & 57 of the Biological Diversity Act, 2002.

Please acknowledge receipt of this communication.

Yours faithfully,

J. Justin Mohan
(J. Justin Mohan)
Secretary, NBA

Encl.: as above.

Copy to: Member Secretary, Andhra Pradesh Biodiversity Board, Flat No.210 Walnut Block, Raintree Park, Nagarjuna Nagar, Opp. Nagarjuna University, NH-5, Guntur District, Andhra Pradesh - 522 508.



ఆంధ్రప్రదేశ్ ఆంధ్ర ప్రదేశ్ ANDHRA PRADESH
Sl.No. 5889 Date : 10.09.2020 Rs.20/-

Sold to:- T.E GOPAL KRISHNA MURTHY S/o SUBBA RAO, BAPATLA
For Whom:- PRINCIPAL BAPATLA COLLEGE OF PHARMACY, BAPATLA

72AA 766188
PERLI PRA. SANKAR DEEVENA KUMAR
LICENSED STAMP VENDOR
RL.No. 07-20-003-2020
R.L.No. 07-20-002/2017, L.No. 07-20-001/2011
NANDIRAJUTHOTA, BAPATLA (M)
Cell: 9440453430

AGREEMENT FOR ACCESS AND BENEFIT SHARING

(Form-III – For filing applications for obtaining any Intellectual Property Right)

(Under the Biological Diversity Act, 2002 and Rules, 2004 and Guidelines on ABS Regulations, 2014)

This Agreement is made and entered on this 7th day of September- 2020 at Chennai, India

Between

National Biodiversity Authority, a statutory body established under the Biological Diversity Act, 2002, having its head office at 5th Floor, TICEL Bio Park, Taramani, Chennai-600 113, Tamil Nadu, India (hereafter "NBA"), acting through and represented by the Secretary, NBA/authorized signatory of NBA, being the person authorised to execute this Agreement.

And

Dr. Talasila E. Gopal Krishna Murthy, citizen of India, having address at Bapatla College of Pharmacy, Bapatla, Guntur District, Andhra Pradesh - 522101., hereafter the "Applicant".

Hereafter referred to as the "Parties" and individually as a "Party".


PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

WHEREAS the NBA is the authority established under the Biological Diversity Act, 2002 (hereafter "**the Act**") authorised to grant approval for the purpose set forth herein and to determine terms and conditions to secure fair and equitable sharing of benefits arising out of the use of biological resources, knowledge and practices associated with their use;

WHEREAS the Applicant has submitted an application in Form III (Appl.no 3964 dated 09.03.2020) under the Biological Diversity Rules, 2004 (hereafter the "**Rules, 2004**") to seek prior approval from NBA;

WHEREAS under the Rules and the guidelines on access to biological resources and/or associated knowledge and benefit sharing regulations, 2014 made under the Act, the approval shall be in the form of a written agreement duly executed between the Parties (hereafter the "**Agreement**");

AND the Parties have entered into this Agreement for access and benefit sharing according to the terms and conditions set out below.

NOW the Parties agree as follows:

1. Definition

For the purpose of this Agreement, the expression "**Effective Date**" shall mean the date on which both the parties sign this Agreement. In case the parties sign on different dates, the effective date shall be the date signed by NBA;

2. Terms and Conditions of the Agreement

2.1 Grant of approval

The NBA hereby grants approval for filing applications for obtaining Intellectual Property Right ("**IPR**") over the invention as described in **Annex B**, only in the countries mentioned in **Annex D** subject to such other terms and conditions set forth in this Agreement.


2.2 Scope and extent


The approval is limited to the extent and for the purpose for which it is accorded under the appropriate Annexures.

2.3 Period

2.3.1 Period of Agreement - This Agreement shall remain in force from the effective date of this Agreement till the subsistence of the IPR for which approval was granted.

2.3.2 Notwithstanding the above, this Agreement shall remain in force until the applicant fulfils all the obligations as required under this Agreement.




PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

2.4 Transfer to third party or by operation of law

In the event that the IPR of the Applicant is transferred by way of an assignment, licensing or by operation of law (including in cases of death or bankruptcy or dissolution of a company), all rights and obligations under this Agreement shall be binding upon the assignee or licensee or legal representative or the person to whom the IPR devolves as the case may be.

In the case of above eventuality, the legal representative or the assignee or licensee or the person to whom the IPR has devolved shall intimate and submit such relevant documents to NBA within **sixty days** of the happening of such event. Upon receiving such intimation, NBA may amend the agreement under clause 13 of this Agreement so as to ensure fair and equitable benefit sharing.

3. Obligations of the Applicant

3.1. The Applicant shall share benefits as stipulated under Schedule A.

3.2 The permission granted to the Applicant is limited to that granted by the NBA in Annex-B of Schedule B of this Agreement. All other activities of the Applicant which require NBA's prior approval will need to be applied separately in the concerned Form under Rules, 2004. Further, the Applicant shall intimate to the NBA in the event of seeking IPR in other territories and thereafter the Agreement's annex will be suitably amended.

3.3 The Applicant shall abide by all the terms and conditions of the Agreement and other related legislations in force including any clearances required from the concerned authorities, such as the Chief Wildlife Warden in protected areas and forest authorities in other forest areas.

3.4 The Applicant shall, in the event that the Applicant forms a body corporate, association or organization under section 3(2)(c), intimate the same and submit all the related documents to NBA within **90 days** from the completion of that event. Subsequent to the said intimation, NBA shall decide whether this Agreement shall be amended as per clause 13 or a fresh approval is required. NBA's decision in this regard shall be final.

3.5 The Applicant shall have India as its first source of supply and/or cultivation of biological resources for the commercialization of IPR as the case may be.

3.6 The Applicant shall in the event of any breach of this Agreement pay such compensation commensurate with the damage incurred to the Republic of India or to the benefit claimers as decided by the appropriate forum.



T. Subalakshmi
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

- 3.7 The Applicant shall keep all the relevant records that serve as a proof of the monetary benefits shared by the Applicant with NBA or the concerned benefit claimers as the case may be, together with supporting documents. This may be submitted to NBA as specified from time to time and such records shall be retained for at least three (3) years after the termination of this Agreement.
- 3.8 NBA shall have the right to regulate /monitor the activities approved under this Agreement, by itself or through any appropriate agency as it may deem fit.
- 3.9 Whenever the Applicant requires to access biological resources for commercial utilization of the IPR for which approval is granted under this Agreement, the Applicant shall take prior approval of NBA under Form I of the Rules, 2004 or the respective form of the concerned State biodiversity rules.
- 3.10 The Applicant shall notify in writing to the NBA about the grant of IPR and the assignment or licensing of such IPR, if any, in each of the countries/territories as specified in Annex D, within **60 days** from the date of grant of the said IPR.
- 3.11 The Applicant shall, in case of any modification or improvement or commercialization of the invention/ product/process of the IPR, intimate to NBA within **45 days** of the happening of such event. Based on such intimation, NBA may decide to review the earlier approval and its decision shall be final.
- 3.12 The Applicant, in the event of decision to withdraw or abandon the patent application, shall intimate to NBA within 45 days of the happening of such event.

3.13 *Status Reports*

3.13.1 The Applicant shall submit a status report for each reporting year not later than two months of the end of each reporting year in the prescribed format of NBA.

3.13.2 During the subsistence of this Agreement, the Applicant shall submit separate status reports in relation to each of the countries/territories mentioned in Annex D for each reporting year in the prescribed format of NBA. This shall be submitted not later two months of the end of each reporting year.

3.13.3 Non-submission of the status reports within the stipulated time period in relation to any of the countries/territories mentioned in Annex D will be construed as a breach for which penalty may be imposed by NBA under clause 6 of this Agreement.

3.13.4 The Applicant shall submit a copy of Form 27 of the Indian Patent Rules, 2015 within one month of submitting the same to the Patent Office.



T. G. Balakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

4. Fair and Equitable Benefit Sharing

- 4.1 The Applicant shall share benefits as per Schedule A in monetary and/or non-monetary mode.
- 4.2 The Applicant shall make the payment preferably by way of demand draft or any other approved mode of payment and the same shall be drawn in the name of "National Biodiversity Fund".

5. Written Notice

- 5.1 Any communication including serving notices under this Agreement, shall be in writing and communicated by Registered post with acknowledgement due or e-mail or fax in the address mentioned hereunder.

If to NBA:

The Secretary, NBA, 5th Floor, TICEL Bio Park, Taramani, Chennai-600 113, Tamil Nadu, India. secretary@nba.nic.in

If to the Applicant

Dr. Talasila E Gopala Krishna Murthy, Principal, Bapatla College of Pharmacy, Bapatla, Guntur District, Andhra Pradesh - 522101. Mobile - +91-9912342094. Email: bcp.principal@gmail.com

- 5.2 Notice is deemed to have been given if duly communicated in accordance with the Indian Contract Act, 1872 and the Information Technology Act, 2000 and related Indian legislations.
- 5.3 Any change in the address/email address/fax of the Parties shall be notified to the other Party within **15 days** of such change by way of a notice.

6. Procedure for imposing penalty in case of breach.

- 6.1 If NBA has prima facie evidence to the effect that the Applicant has committed a breach of any of the terms of this Agreement, NBA shall send a written notice to the Applicant communicating the default or details of the breach within **30 days** of the discovery of that event, giving an opportunity to be heard to the Applicant.

- 6.2 The Applicant shall within **30 days** from the date of serving of such notice respond in writing to NBA.




T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

- 6.3 Upon receiving such explanation from the Applicant, NBA shall take into account the explanation and decide if there is a breach committed by Applicant or not. In the event that the NBA does not receive such explanation from the Applicant, NBA shall send final notice to the Applicant. If the Applicant responds within 30 days, NBA shall be taken into account the explanation and decide on the breach. If the Applicant does not respond within 30 days, the Applicant will be deemed to be in breach of this Agreement.
- 6.4 In the event that the Applicant does not respond to the final opportunity given by NBA or in the event that NBA decides that there is a breach of this Agreement, NBA has the power to issue any order executable under section 53 of the Act including imposition of penalty of a sum which may extend to one lakh rupees as determined by NBA from time to time and in addition direct the Applicant to pay such compensation commensurate with the damage incurred by the Republic of India or the benefit claimers.
- 6.5 Penalties imposed by NBA under this clause shall be in addition to any recovery of any monetary benefits due, compliance with directions or orders issued by NBA and without prejudice to any other rights under this Agreement.
- 6.6 Notwithstanding any of the clauses above, in addition to imposition of penalty, if the breach or default committed by the Applicant amounts to violation of any of the provisions of the Act, appropriate legal proceedings shall be initiated under Section 61 of the Act.

7. Termination and Revocation

- 7.1 Subject to clause 2.3, the Agreement shall stand automatically terminated on the completion of the period agreed to between the Parties including the period of extension agreed to, if any. On termination, the Applicant shall comply with obligation under clause 7.3.
- 7.2 During the subsistence of this Agreement, the Applicant shall have an option to initiate termination of this Agreement by sending a request to NBA in the form of a notice stating valid reasons for the same. On receipt of the same, it shall be the discretion of NBA to accept the reasons specified by the Applicant or not. In the event of its decision to terminate, NBA shall intimate to the applicant by way of a notice within **90 days** of making the decision. On receipt of such a notice from NBA, the applicant shall comply with clause 8.3.
- 7.3 Upon termination of the Agreement, the Applicant shall pay all outstanding dues including the benefit sharing amount and submit status report dues, if any, due until then by the Applicant within 45 days of the date of termination of this Agreement.
- 7.4 NBA may withdraw the approval granted and revoke this Agreement in case of occurrence of any of the conditions mentioned in Rule 15 of the Rules, 2004 or if the applicant performs activities contrary to any restriction or prohibition imposed by NBA or under the Act and Rules, 2004.



T. S. Sathyanarayanan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

8. Liabilities and Indemnification


- 8.1 NBA shall not be liable for any loss or damage whatsoever caused to the Applicant due to revocation of approval for access and/or termination of this Agreement on any grounds whatsoever.
- 8.2 The Applicant shall be solely responsible for any claims by third parties arising from the Applicant's acts or omissions in the course of performing this Agreement and under no circumstances shall the NBA be held responsible or liable for any claims by such third parties.
- 8.3 The Applicant shall pay such sum for breach committed by the Applicant as determined by NBA under clause 6 of this Agreement which is in addition to the compensation commensurate with the damage incurred by the Republic of India or the benefit claimers that the Applicant is liable to pay as decided by the appropriate forum.
- 8.4 The Applicant shall indemnify and save NBA and its employees, members and officers, from and against all claims, demands, losses, damages, costs (including attorney fees), actions, suits or other proceedings, all in any manner based upon, arising out of, related to, occasioned by or attributable to, any acts or conduct of the Applicant, its employees or agents, (whether by reason of negligence or otherwise) in the performance by or on behalf of the Applicant of the provisions of this Agreement or any activity undertaken or purported to be undertaken under the authority or pursuant to the terms of this Agreement.


9. Confidentiality

- 9.1 Upon request from the Applicant, NBA shall keep as confidential that information which is desired to be kept as confidential by the Applicant.
- 9.2 Notwithstanding the above, confidential information may be disclosed by NBA to the extent required by any law or regulation or order of any authority established by law having jurisdiction over any of the Parties or in the opinion of NBA such disclosure becomes necessary to deal with any emergency situations, or national or public interest.

10. Arbitration

- 10.1 In case any dispute or difference arises out of the interpretation of any clauses of the Agreement, either of the Parties may give the other Party a notice clearly identifying and providing details of the dispute. On receipt of such notice by the other Party, the Parties shall try to settle such dispute/difference amicably between them by negotiating in good faith within **30 days** of the receipt of such notice.
- 10.2 If the dispute or difference is not resolved by such negotiations within the period mentioned, the dispute or difference shall be referred to the sole arbitrator appointed by NBA.




PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

10.3 The arbitration shall be governed by the Arbitration and Conciliation Act, 1996 and the rules framed thereunder. The place of arbitration shall be Chennai, India.

10.4 The award of the Arbitrator shall be final, conclusive and binding on the Parties. The Arbitrator shall be competent to decide whether any matter or dispute or difference referred to him falls within the purview of arbitration.

11. Governing Law and Jurisdiction

11.1 This Agreement is governed by and is to be construed in accordance with the laws of India without regard to the principles of conflicts of laws subject to the provisions of arbitration clauses to this Agreement.

11.2 In the event of a dispute or difference not settled through arbitration as specified in clause 11, the Parties shall irrevocably and unconditionally submit to the appropriate court of jurisdiction in Chennai.

11.3 As regards all other aspects and the terms and conditions not provided for this in this Agreement, they shall be governed by the provisions of the Act read with Rules and Regulations made thereunder.

11.4 This Agreement shall not in any way constitute or be presumed to constitute a partnership or a joint venture or a joint enterprise in any way or for any purpose between the Parties hereto or make the parties in any way liable as partners of or as agents for one another.

12. Severability

12.1 If any part of this Agreement is declared or held improper or unjustifiable or invalid by a Court of Law for any reason, the deficiency or invalidity of that part shall not affect the validity of the remainder which will continue in full force and effect and be construed as if the Agreement had been executed without the invalid portion.

12.2 However the remainder of the Agreement shall not come into force unless the remainder is consistent with the declaration or order or judgment of the Court.

13. Amendment

No amendment to this Agreement shall be valid or binding upon the Parties, unless agreed upon by the Parties, in writing, and signed on behalf of each Party by their duly and legally authorized persons and such amendment shall be made as a supplementary agreement along with Annexes, as applicable.

14. Entirety of Agreement: This Agreement constitutes the culmination of all prior negotiations, understanding, representations and commitments and sets down the complete terms and conditions of Agreement between the parties as to the subject matter.




T. G. Subashini
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

15. Annex and Schedules

- a. The Schedules and their Annexes attached to this Agreement or Schedule that may be added subsequently by way of an amendment under the provisions of this Agreement, shall form an integral part of this Agreement and shall be binding on the Parties.
- b. This Agreement has been executed in duplicate, each of which shall be deemed to be original; one shall be retained by the NBA and other by the Applicant and both shall constitute one and the same instrument.


IN WITNESS WHEREOF the parties hereto have signed in this Agreement on the day month and the year aforesaid in this Agreement.



(S/d with date)

Signed by the Authorized person of the Authority





(S/d with date)

Signed by the Applicants

PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

For National Biodiversity Authority

Witnesses

1. Signature

Name

Address


Dr. Narendran T
Technical Officer (IPR) / Technical Officer (IPR)
National Biodiversity Authority
Government of India
5th Floor, TICEL Bio Park,
CSIR Road, Taramani, Chennai - 600 113

2. Signature

Name

Address


K. CHITRARASU
Advisor (Law)
National Biodiversity Authority,
Govt. of India
TICEL Bio Park, 5th Floor,
CSIR Road, Taramani,
Chennai - 600 113.

For the Applicant

Witnesses

1. Signature

Name: Y. Sushma

Address: Asst. Professor,
Bapatla College of Pharmacy,
Bapatla-522101, Guntur Dist., A.P.

2. Signature

Name: T. Vijay Sekhar

Address: Jr. Assistant, Bapatla
College of Pharmacy, Bapatla-
522101, Guntur Dist., A.P.

SCHEDULE A - BENEFIT SHARING COMPONENT

- (i) Where the applicant himself commercializes the process/product/innovation, the monetary benefit sharing shall be **0.2%** on the annual gross ex-factory sale minus government taxes.
- (ii) Where the applicant assigns/licenses the process/product/innovation to a third party for commercialization, the applicant shall pay to NBA **3.0%** of the fee received (in any form including the license/assignee fee) and **2.0%** of the royalty amount received annually from the assignee/licensee.

SCHEDULE B - ANNEXES TO BE ATTACHED

ANNEX A - Details of biological resources and/or knowledge associated thereto and geographical locations

ANNEX B - Title, Details of the invention and the patent application number in case patent has been filed

ANNEX C - Authorisation made by the Applicant (*if any*) for signing the Agreement and/or filing IPR

ANNEX D - Name of the countries/territories where IPR over the invention is sought to be taken

T. Gokulakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

2. Sushis Roshay



Annexure-A

Details of biological resources and/or knowledge associated thereto and geographical locations

Collagen is extracted from the animal bones as per standard established procedure. The animal bones were collected from the slater house located at Rajivgandhi Colony, Railpet, Bapatla.

T. Subalaxshmi
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



ANNEX - B

Title, Details of the invention and the patent application number in case patent has been filed



Controller General of Patents, Designs and Trademarks
Department of Industrial Policy and Promotion
Ministry of Commerce and Industry

Application Details

APPLICATION NUMBER	4504/CHE/2014
APPLICATION TYPE	ORDINARY APPLICATION
DATE OF FILING	16/09/2014
APPLICANT NAME	TALASILA ESWARA GOPALA KRISHNA MURTHY
TITLE OF INVENTION	STATIN IMPREGNATED COLLAGEN BASED DERMAL SCAFFOLDS MADE OF COW URINE
FIELD OF INVENTION	BIOTECHNOLOGY
E-MAIL (As Per Record)	
ADDITIONAL-EMAIL (As Per Record)	gopalakrishnatalasila@yahoo.com
E-MAIL (UPDATED Online)	
PRIORITY DATE	
REQUEST FOR EXAMINATION DATE	11/04/2017
PUBLICATION DATE (U/S 11A)	01/07/2016
FIRST EXAMINATION REPORT DATE	17/10/2019
REPLY TO FER DATE	23/04/2020

T. G. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



ANNEX - C

Authorisation made by the Applicant (*if any*) for signing the Agreement and/or filing IPR

Answer: --- Not Applicable ---

T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



ANNEX - D

Name of the countries/territories where IPR over the invention is sought to be taken

Answer: India

T. Gopalakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

[Handwritten signature]





National Biodiversity Authority

राष्ट्रीय जैव विविधता प्राधिकरण
(Statutory body of Ministry of Environment, Forest and Climate Change, Government of India)



J. Justin Mohan, IFS
Secretary

+91 44 2254 1071

+91 44 2254 1074

secretary@nba.nic.in @ www.nbaindia.org

5th Floor, CSIR Road, TICEL Bio Park,
Taramani, Chennai - 600 113, Tamil Nadu, India.

5 वा तल, सीएसआईआर रोड, टाइकल बायो पार्क,
तरामनि, चेन्नई - 600113 तमिलनाडु, भारत.

NBA/IPR Appl/3888/20-21/ 2892

16.11.2020

To

Dr. Talasila E Gopala Krishna Murthy
Principal,
Bapatla College of Pharmacy, Bapatla,
Guntur District, Andhra Pradesh - 522101
Mobile - +91-9912342094
Email: bcp.principal@gmail.com

Sir/Madam,

Sub: Approval for applying for IPR as per Section 6 of the Biological Diversity Act, 2002 read with Rules 18 of the Biological Diversity Rules, 2004 – reg.


Ref: Application in Form-III No. 3888

With reference to your application cited in reference on the subject cited above to facilitate for IPR on patent application no. (201641014417) the invention titled “**Pharmaceutical compositions comprising rutin isolated from *Dactyloctenium aegyptium***” using the biological resource *Dactyloctenium aegyptium* has been approved by the National Biodiversity Authority subject to the conditions laid down namely in the agreement.

In this regard, I am enclosing herewith one mutually signed stamp paper agreement executed between National Biodiversity Authority and the applicant for the applicant's reference and compliance. It is also to inform you that breach of the terms of agreement and provisions of the Biological Diversity Act, 2002 and Biological Diversity Rules, 2004 made thereunder will invite imposition of penalties as per Section 55, 56 & 57 of the Biological Diversity Act, 2002.

Please acknowledge receipt of this communication.

Yours faithfully,


(J. Justin Mohan)
Secretary, NBA

Encl.: As above.

Copy to:

Member Secretary, Andhra Pradesh Biodiversity Board, Flat No.210 Walnut Block, Raintree Park,
Nagarjuna Nagar, Opp. Nagarjuna University, NH-5, Guntur District, Andhra Pradesh - 522508



ఆంధ్రప్రదేశ్ ఆంధ్ర ప్రదేశ్ ANDHRA PRADESH

72AA 767862

SL No. 3379 Date 07-09-2020

Sold to: T. Talasila E. Gopala Krishna Murthy, citizen of India, having address at Bapatla College of Pharmacy, Bapatla, Guntur District, Andhra Pradesh - 522101, hereafter the "Applicant".

For Whom:

DAMMU RAJESWARA RAO
Licensed Stamp Vendor
L.No.07-20-010/2013

R.L.No.07-20-004/2020 To 31-12-2022
D.No. 11-7-3, Kalidas Street, Bapatla
Guntur Dt. A.P. Pin No-522101
No. : 6555033944

AGREEMENT FOR ACCESS AND BENEFIT SHARING

(Form-III - For filing applications for obtaining any Intellectual Property Right)

(Under the Biological Diversity Act, 2002 and Rules, 2004 and Guidelines on ABS Regulations, 2014)


This Agreement is made and entered on this 16th day of September, 2020 at Chennai, India

Between

National Biodiversity Authority, a statutory body established under the Biological Diversity Act, 2002, having its head office at 5th Floor, TICEL Bio Park, Taramani, Chennai-600 113, Tamil Nadu, India (hereafter "NBA"), acting through and represented by the Secretary, NBA/authorized signatory of NBA, being the person authorised to execute this Agreement.

And
Dr. Talasila E. Gopala Krishna Murthy, citizen of India, having address at Bapatla College of Pharmacy, Bapatla, Guntur District, Andhra Pradesh - 522101, hereafter the "Applicant".

Hereafter, referred to as the "Parties" and individually as a "Party".



T. Talasila E. Gopala Krishna Murthy
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

WHEREAS the NBA is the authority established under the Biological Diversity Act, 2002 (hereafter "the Act") authorised to grant approval for the purpose set forth herein and to determine terms and conditions to secure fair and equitable sharing of benefits arising out of the use of biological resources, knowledge and practices associated with their use;

WHEREAS the Applicant has submitted an application in Form III (Appl.no 3888 dated 13.05.2020) under the Biological Diversity Rules, 2004 (hereafter the "Rules, 2004") to seek prior approval from NBA;

WHEREAS under the Rules and the guidelines on access to biological resources and/or associated knowledge and benefit sharing regulations, 2014 made under the Act, the approval shall be in the form of a written agreement duly executed between the Parties (hereafter the "Agreement");

AND the Parties have entered into this Agreement for access and benefit sharing according to the terms and conditions set out below.

NOW the Parties agree as follows:

1. Definition

For the purpose of this Agreement, the expression "*Effective Date*" shall mean the date on which both the parties sign this Agreement. In case the parties sign on different dates, the effective date shall be the date signed by NBA;

2. Terms and Conditions of the Agreement

2.1 Grant of approval

The NBA hereby grants approval for filing applications for obtaining Intellectual Property Right ("IPR") over the invention as described in **Annex B**, only in the countries mentioned in **Annex D** subject to such other terms and conditions set forth in this Agreement.


2.2 Scope and extent

The approval is limited to the extent and for the purpose for which it is accorded under the appropriate Annexures.

2.3 Period

2.3.1 *Period of Agreement* - This Agreement shall remain in force from the effective date of this Agreement till the subsistence of the IPR for which approval was granted.

2.3.2 Notwithstanding the above, this Agreement shall remain in force until the applicant fulfils all the obligations as required under this Agreement.



T. Gobalaprakash
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

2.4 Transfer to third party or by operation of law

In the event that the IPR of the Applicant is transferred by way of an assignment, licensing or by operation of law (including in cases of death or bankruptcy or dissolution of a company), all rights and obligations under this Agreement shall be binding upon the assignee or licensee or legal representative or the person to whom the IPR devolves as the case may be.

In the case of above eventuality, the legal representative or the assignee or licensee or the person to whom the IPR has devolved shall intimate and submit such relevant documents to NBA within sixty days of the happening of such event. Upon receiving such intimation, NBA may amend the agreement under clause 13 of this Agreement so as to ensure fair and equitable benefit sharing.

3. Obligations of the Applicant

3.1. The Applicant shall share benefits as stipulated under Schedule A.

3.2 The permission granted to the Applicant is limited to that granted by the NBA in Annex-B of Schedule B of this Agreement. All other activities of the Applicant which require NBA's prior approval will need to be applied separately in the concerned Form under Rules, 2004. Further, the Applicant shall intimate to the NBA in the event of seeking IPR in other territories and thereafter the Agreement's annex will be suitably amended.

3.3 The Applicant shall abide by all the terms and conditions of the Agreement and other related legislations in force including any clearances required from the concerned authorities, such as the Chief Wildlife Warden in protected areas and forest authorities in other forest areas.

3.4 The Applicant shall, in the event that the Applicant forms a body corporate, association or organization under section 3(2)(c), intimate the same and submit all the related documents to NBA within 90 days from the completion of that event. Subsequent to the said intimation, NBA shall decide whether this Agreement shall be amended as per clause 13 or a fresh approval is required. NBA's decision in this regard shall be final.

3.5 The Applicant shall have India as its first source of supply and/or cultivation of biological resources for the commercialization of IPR as the case may be.

3.6 The Applicant shall in the event of any breach of this Agreement pay such compensation commensurate with the damage incurred to the Republic of India or to the benefit claimers as decided by the appropriate forum.



T. G. Subramanian
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

- 3.7 The Applicant shall keep all the relevant records that serve as a proof of the monetary benefits shared by the Applicant with NBA or the concerned benefit claimers as the case may be, together with supporting documents. This may be submitted to NBA as specified from time to time and such records shall be retained for at least three (3) years after the termination of this Agreement.
- 3.8 NBA shall have the right to regulate /monitor the activities approved under this Agreement, by itself or through any appropriate agency as it may deem fit.
- 3.9 Whenever the Applicant requires to access biological resources for commercial utilization of the IPR for which approval is granted under this Agreement, the Applicant shall take prior approval of NBA under Form I of the Rules, 2004 or the respective form of the concerned State biodiversity rules.
- 3.10 The Applicant shall notify in writing to the NBA about the grant of IPR and the assignment or licensing of such IPR, if any, in each of the countries/territories as specified in Annex D, within **60 days** from the date of grant of the said IPR.
- 3.11 The Applicant shall, in case of any modification or improvement or commercialization of the invention/ product/process of the IPR, intimate to NBA within **45 days** of the happening of such event. Based on such intimation, NBA may decide to review the earlier approval and its decision shall be final.
- 3.12 The Applicant, in the event of decision to withdraw or abandon the patent application, shall intimate to NBA within 45 days of the happening of such event.
- 3.13 *Status Reports*

3.13.1 The Applicant shall submit a status report for each reporting year not later than two months of the end of each reporting year in the prescribed format of NBA.

3.13.2 During the subsistence of this Agreement, the Applicant shall submit separate status reports in relation to each of the countries/territories mentioned in Annex D for each reporting year in the prescribed format of NBA. This shall be submitted not later two months of the end of each reporting year.

3.13.3 Non-submission of the status reports within the stipulated time period in relation to any of the countries/territories mentioned in Annex D will be construed as a breach for which penalty may be imposed by NBA under clause 6 of this Agreement.

3.13.4 The Applicant shall submit a copy of Form 27 of the Indian Patent Rules, 2015 within one month of submitting the same to the Patent Office.



T. G. Subalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

4. Fair and Equitable Benefit Sharing

- 4.1 The Applicant shall share benefits as per Schedule A in monetary and/or non-monetary mode.
- 4.2 The Applicant shall make the payment preferably by way of demand draft or any other approved mode of payment and the same shall be drawn in the name of "National Biodiversity Fund".

5. Written Notice

- 5.1 Any communication including serving notices under this Agreement, shall be in writing and communicated by Registered post with acknowledgement due or e-mail or fax in the address mentioned hereunder.

If to NBA:

The Secretary, NBA, 5th Floor, TICEL Bio Park, Taramani, Chennai-600 113, Tamil Nadu, India. secretary@nba.nic.in

If to the Applicant


Dr. Talasila E Gopala Krishna Murthy, Principal, Bapatla College of Pharmacy, Bapatla, Guntur District, Andhra Pradesh - 522101. Mobile - +91-9912342094. Email: bcp.principal@gmail.com

- 5.2 Notice is deemed to have been given if duly communicated in accordance with the Indian Contract Act, 1872 and the Information Technology Act, 2000 and related Indian legislations.
- 5.3 Any change in the address/email address/fax of the Parties shall be notified to the other Party within 15 days of such change by way of a notice.

6. Procedure for imposing penalty in case of breach.

- 6.1 If NBA has prima facie evidence to the effect that the Applicant has committed a breach of any of the terms of this Agreement, NBA shall send a written notice to the Applicant communicating the default or details of the breach within 30 days of the discovery of that event, giving an opportunity to be heard to the Applicant.

- 6.2 The Applicant shall within 30 days from the date of serving of such notice respond in writing to NBA.




T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

- 6.3 Upon receiving such explanation from the Applicant, NBA shall take into account the explanation and decide if there is a breach committed by Applicant or not. In the event that the NBA does not receive such explanation from the Applicant, NBA shall send final notice to the Applicant. If the Applicant responds within 30 days, NBA shall be taken into account the explanation and decide on the breach. If the Applicant does not respond within 30 days, the Applicant will be deemed to be in breach of this Agreement.
- 6.4 In the event that the Applicant does not respond to the final opportunity given by NBA or in the event that NBA decides that there is a breach of this Agreement, NBA has the power to issue any order executable under section 53 of the Act including imposition of penalty of a sum which may extend to one lakh rupees as determined by NBA from time to time and in addition direct the Applicant to pay such compensation commensurate with the damage incurred by the Republic of India or the benefit claimers.
- 6.5 Penalties imposed by NBA under this clause shall be in addition to any recovery of any monetary benefits due, compliance with directions or orders issued by NBA and without prejudice to any other rights under this Agreement.
- 6.6 Notwithstanding any of the clauses above, in addition to imposition of penalty, if the breach or default committed by the Applicant amounts to violation of any of the provisions of the Act, appropriate legal proceedings shall be initiated under Section 61 of the Act.

7. Termination and Revocation

- 7.1 Subject to clause 2.3, the Agreement shall stand automatically terminated on the completion of the period agreed to between the Parties including the period of extension agreed to, if any. On termination, the Applicant shall comply with obligation under clause 7.3.
- 7.2 During the subsistence of this Agreement, the Applicant shall have an option to initiate termination of this Agreement by sending a request to NBA in the form of a notice stating valid reasons for the same. On receipt of the same, it shall be the discretion of NBA to accept the reasons specified by the Applicant or not. In the event of its decision to terminate, NBA shall intimate to the applicant by way of a notice within **90 days** of making the decision. On receipt of such a notice from NBA, the applicant shall comply with clause 8.3.
- 7.3 Upon termination of the Agreement, the Applicant shall pay all outstanding dues including the benefit sharing amount and submit status report dues, if any, due until then by the Applicant within 45 days of the date of termination of this Agreement.

- 7.4 NBA may withdraw the approval granted and revoke this Agreement in case of occurrence of any of the conditions mentioned in Rule 15 of the Rules, 2004 or if the applicant performs activities contrary to any restriction or prohibition imposed by NBA or under the Act and Rules, 2004.



T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

8. Liabilities and Indemnification

- 8.1 NBA shall not be liable for any loss or damage whatsoever caused to the Applicant due to revocation of approval for access and/or termination of this Agreement on any grounds whatsoever.
- 8.2 The Applicant shall be solely responsible for any claims by third parties arising from the Applicant's acts or omissions in the course of performing this Agreement and under no circumstances shall the NBA be held responsible or liable for any claims by such third parties.
- 8.3 The Applicant shall pay such sum for breach committed by the Applicant as determined by NBA under clause 6 of this Agreement which is in addition to the compensation commensurate with the damage incurred by the Republic of India or the benefit claimers that the Applicant is liable to pay as decided by the appropriate forum.
- 8.4 The Applicant shall indemnify and save NBA and its employees, members and officers, from and against all claims, demands, losses, damages, costs (including attorney fees), actions, suits or other proceedings, all in any manner based upon, arising out of, related to, occasioned by or attributable to, any acts or conduct of the Applicant, its employees or agents, (whether by reason of negligence or otherwise) in the performance by or on behalf of the Applicant of the provisions of this Agreement or any activity undertaken or purported to be undertaken under the authority or pursuant to the terms of this Agreement.

9. Confidentiality

- 9.1 Upon request from the Applicant, NBA shall keep as confidential that information which is desired to be kept as confidential by the Applicant.
- 9.2 Notwithstanding the above, confidential information may be disclosed by NBA to the extent required by any law or regulation or order of any authority established by law having jurisdiction over any of the Parties or in the opinion of NBA such disclosure becomes necessary to deal with any emergency situations, or national or public interest.

10. Arbitration

- 10.1 In case any dispute or difference arises out of the interpretation of any clauses of the Agreement, either of the Parties may give the other Party a notice clearly identifying and providing details of the dispute. On receipt of such notice by the other Party, the Parties shall try to settle such dispute/difference amicably between them by negotiating in good faith within 30 days of the receipt of such notice.



T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

- 10.2 If the dispute or difference is not resolved by such negotiations within the period mentioned, the dispute or difference shall be referred to the sole arbitrator appointed by NBA.
- 10.3 The arbitration shall be governed by the Arbitration and Conciliation Act, 1996 and the rules framed thereunder. The place of arbitration shall be Chennai, India.
- 10.4 The award of the Arbitrator shall be final, conclusive and binding on the Parties. The Arbitrator shall be competent to decide whether any matter or dispute or difference referred to him falls within the purview of arbitration.

11. Governing Law and Jurisdiction

- 11.1 This Agreement is governed by and is to be construed in accordance with the laws of India without regard to the principles of conflicts of laws subject to the provisions of arbitration clauses to this Agreement.
- 11.2 In the event of a dispute or difference not settled through arbitration as specified in clause 11, the Parties shall irrevocably and unconditionally submit to the appropriate court of jurisdiction in Chennai.
- 11.3 As regards all other aspects and the terms and conditions not provided for this in this Agreement, they shall be governed by the provisions of the Act read with Rules and Regulations made thereunder.
- 11.4 This Agreement shall not in any way constitute or be presumed to constitute a partnership or a joint venture or a joint enterprise in any way or for any purpose between the Parties hereto or make the parties in any way liable as partners of or as agents for one another.

12. Severability

- 12.1 If any part of this Agreement is declared or held improper or unjustifiable or invalid by a Court of Law for any reason, the deficiency or invalidity of that part shall not affect the validity of the remainder which will continue in full force and effect and be construed as if the Agreement had been executed without the invalid portion.
- 12.2 However the remainder of the Agreement shall not come into force unless the remainder is consistent with the declaration or order or judgment of the Court.

13. Amendment

No amendment to this Agreement shall be valid or binding upon the Parties, unless agreed upon by the Parties, in writing, and signed on behalf of each Party by their duly and legally authorized persons and such amendment shall be made as a supplementary agreement along with Annexes, as applicable.



T. Subalakshmi
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

13. Amendment

No amendment to this Agreement shall be valid or binding upon the Parties, unless agreed upon by the Parties, in writing, and signed on behalf of each Party by their duly and legally authorized persons and such amendment shall be made as a supplementary agreement along with Annexes, as applicable.

14. Entirety of Agreement

This Agreement constitutes the culmination of all prior negotiations, understanding, representations and commitments and sets down the complete terms and conditions of Agreement between the parties as to the subject matter.

15. Annex and Schedules

- a. The Schedules and their Annexes attached to this Agreement or Schedule that may be added subsequently by way of an amendment under the provisions of this Agreement shall form an integral part of this Agreement and shall be binding on the Parties.
- b. This Agreement has been executed in duplicate, each of which shall be deemed to be original; one shall be retained by the NBA and other by the Applicant and both shall constitute one and the same instrument.

IN WITNESS WHEREOF the parties hereto have signed in this Agreement on the day month and the year aforesaid in this Agreement.

(s/d with date)

Signed by the Authorized person of the Authority

For National Biodiversity Authority

Witnesses

1. Signature

Name

Address

2. Signature

Name

Address

डॉ. नरेन्द्रन टी / Dr. Narendra T
संरक्षणीय अधिकारी (आर्थिक) / Technical Officer (IPR)
राष्ट्रीय जैव विविधता प्राधिकरण / National Biodiversity Authority
भारत सरकार / Government of India
5वां तल, टिगल बायोपार्क / 5th Floor, TICEL Bio Park,
तरामनी, चेन्नई / Taramani, Chennai- 600113

K. CHITRARASU
Advisor (Law)
National Biodiversity Authority,
Govt. of India
TICEL Bio Park, 5th Floor,
CSIR Road, Taramani,
Chennai - 600 113.

T. Gopalakrishna
28/10/2020
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Signed by the Applicants

For the Applicant

Witnesses

1. Signature

Name: Y. Sushma

Address: Assistant
Professor, Bapatla College of
Pharmacy, Bapatla-522101

2. Signature T. Vijay Sekhar

Name: T. Vijay Sekhar

Address: Jr. Assistant,
Bapatla College of Pharmacy,
Bapatla-522101

T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

SCHEDULE A – BENEFIT SHARING COMPONENT

Higher benefit sharing component is fixed, due to use of traditional knowledge in the invention

- (i) Where the applicant himself commercializes the process/product/innovation, the monetary benefit sharing shall be 0.4% on the annual gross ex-factory sale minus government taxes.
- (ii) Where the applicant assigns/licenses the process/product/innovation to a third party for commercialization, the applicant shall pay to NBA 4.0% of the fee received (in any form including the license/assignee fee) and 4.0% of the royalty amount received annually from the assignee/licensee.

T. Gopalakrishna
28/10/2020
PRINCIPAL

Bapatla College of Pharmacy
BAPATLA - 522 101.

SCHEDULE B – ANNEXES TO BE ATTACHED

ANNEX A - Details of biological resources and/or knowledge associated thereto and geographical locations

ANNEX B - Title, Details of the invention and the patent application number in case patent has been filed

ANNEX C - Authorisation made by the Applicant (if any) for signing the Agreement and/or filing IPR

ANNEX D - Name of the countries/territories where IPR over the invention is sought to be taken



T. Gopalakrishna
28/10/2020
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Annexure-A

Details of biological resources and/or knowledge associated thereto and geographical locations

Detailed description of the invention

The present invention relates to evaluation of antidiabetic potential of different solvent extracts of *Dactyloctenium aegyptium* whole plant in Streptozotocin induced diabetic rats.

The present invention further relates to evaluation of antidiabetic potential of different solvent fractions of best/active extract obtained in the above step.

The present invention also relates to isolation of active constituent responsible for antidiabetic activity from the best/active fraction obtained from the earlier step.

The present invention also relates to conducting solubility and stability studies for Rutin (active constituent) in different buffers.


The present invention also relates to a pharmaceutical composition comprising Rutin and one or more pharmaceutically acceptable excipients.

The present invention also relates to dissolution studies for Rutin tablets in the developed dissolution media.

In the present invention, *Dactyloctenium aegyptium* powder material was subjected to extraction with different solvents like water, hydroalcohol (water: methanol 50:50), ethanol, ethyl acetate, chloroform and n-hexane. All extracts were subjected to phytochemical screening and antidiabetic activity in Streptozotocin induced diabetic rats.

In another embodiment of the present invention, best/active extract obtained in the above step was then fractionated by column chromatography using n-Hexane, Chloroform, Ethyl acetate and Methanol. All fractions were subjected to phytochemical screening and antidiabetic activity in Streptozotocin induced diabetic rats.

In another embodiment of the present invention, best/active fraction was identified from the above study and from which the active constituent responsible for antidiabetic activity was isolated. Its structure was identified and characterized by using suitable analytical techniques like IR spectroscopy, H^1 NMR spectroscopy, C^{13} NMR spectroscopy and Mass spectroscopy.



T. G. Subramanian
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

In another embodiment of the present invention, active constituent obtained in the above step subjected to antidiabetic studies in different doses in Streptozotocin induced diabetic rats and the effective antidiabetic dose was established.

In another embodiment of the present invention, active constituent obtained in the above step subjected to mechanistic studies and the mechanism was established.

In another embodiment of the present invention, solubility and stability studies were conducted for Rutin in different buffers.

In another embodiment, the present invention relates to pharmaceutical composition comprising Rutin prepared by a process comprising the steps of:


- (a) Blending Rutin with one or more pharmaceutically acceptable excipients, and
- (b) Processing into a suitable dosage form.

"Pharmaceutically acceptable excipient/s" is the components added to pharmaceutical formulation to facilitate manufacture, enhance stability, control release, enhance product characteristics, enhance bioavailability, enhance patient acceptability, etc. Pharmaceutically acceptable excipients includes, but not limited to, diluents/fillers, binders, disintegrants, sugars, lubricants, glidants, compression aids, colors, sweeteners, preservatives, surfactants, phospholipids, suspending agents, dispersing agents, film formers, flavors, printing inks, etc.

Binders hold the ingredients in the composition together. Exemplary binders include, but not limited to, cellulose and its derivatives, starch and its derivatives; hydrocolloids; sugars; polyvinyl pyrrolidone and combinations comprising one or more of the foregoing binders. The binder may be used in the range of 1-15% by weight of the composition.

Disintegrants according to the present invention include, but not limited to, water swellable substances, for example, cellulose and its derivatives sodium starch glycolate; ion-exchange resins; starch and modified starches including pregelatinized starch; formalin-casein; and combinations comprising one or more of the foregoing water swellable substances. The disintegrant may be used in the range of 1-20% by weight of the composition.

Lubricants and glidants aids in the processing of powder materials. Exemplary lubricants include, but not limited to, calcium stearate, glycerol behenate, magnesium stearate, mineral oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc, vegetable oil, zinc stearate, and combinations comprising one or more of the foregoing lubricants. Exemplary glidants include, but not limited to, talc, silicon dioxide, cornstarch and the like. The lubricant may be used in the range of 0.1-5% by weight of the composition.



T. Gokulakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Surfactants according to the present invention may be selected from anionic, cationic or non-ionic surface-active agents or surfactants. Suitable anionic surfactants include but not limited to carboxylate, sulfonate, and sulfate ions such as sodium lauryl sulfate (SLS), sodium laurate, dialkyl sodium sulfosuccinates particularly bis-(2-ethylhexyl) sodium sulfosuccinate, sodium stearate, potassium stearate, sodium oleate and the like. Suitable cationic surfactants include but not limited to those containing long chain cations, such as benzalkonium chloride, bis-2- hydroxyethyl oleyl amine or the like. Suitable non-ionic surfactants include but not limited to polyoxyethylene sorbitan fatty acid esters (polysorbates), fatty alcohols such as lauryl, cetyl and stearyl alcohols; glyceryl esters such as the naturally occurring mono-, di-, and tri-glycerides; fatty acid esters of fatty alcohols; polyglycolized glycerides such as gelucire; polyoxyethylene-polyoxypropylene block co-polymer such as Poloxamer and other alcohols such as propylene glycol, polyethylene glycol.

In another embodiment, the present invention also relates to dissolution studies for Rutin tablets in the developed dissolution media.

The following examples further exemplify the invention and are not intended to limit the scope of the invention. It is obvious to those skilled in the art to find out the composition for other dosage forms and substitute the equivalent excipients as described in this specification or with the one known to the industry.

Example 1: Preparation of different solvent extracts of *Dactyloctenium aegyptium*

Extraction was carried out by maceration method using different solvents like water (ADA), hydro alcohol (water: methanol 50:50) (HADA), ethanol (EDA), ethyl acetate (EADA), chloroform (CDA) and n- hexane (NHDA) for 72 hours. Then the contents were filtered and the filtrates were concentrated using rotary flash evaporator, calculated for their yield and stored in desiccators till further use.

Example 2: Preliminary Phytochemical Screening of different solvent extracts of *Dactyloctenium aegyptium*

All extracts were qualitatively tested for the presence of chemical constituents and these were identified by characteristic colour changes using standard procedure.



T. G. Balakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Example 3: Study of antidiabetic activity of different solvent extracts of *Dactyloctenium aegyptium*

All extracts were evaluated for their antidiabetic activity in streptozotocin induced diabetic rats and diabetes was induced by intraperitoneal injection of streptozotocin dissolved in 0.1 M cold sodium citrate buffer, pH 4.5, at a dose of 55 mg/kg. The animals were allowed to drink 5% glucose solution overnight to overcome the drug induced hypoglycaemia. After 72 h, rats with marked hyperglycemia (FBG ≥ 250 mg/dl) were selected and used for the study. All the animals were allowed free access to tap water and pellet diet and maintained at room temperature in plastic cages. All extracts were administered at a dose of 200mg/kg, p.o. and standard drug Gliclazide was administered at a dose of 4.5mg/kg, p.o. for 30 days. Blood samples were collected on 1st, 10th, 20th and 30th day of study from retro orbital venous plexus following the technique described by Coccheto and Bjornsson, allowed to clot and were centrifuged at 3000 rpm for 20 min. The serum was separated and used for the estimation of glucose levels.

From the results inventors found that Ethanolic extract is having best antidiabetic activity and hence it was further subjected to fractionation by column chromatography using different solvents.

Example 4: Preparation of different fractions of Ethanolic extract of *Dactyloctenium aegyptium*


Ethanolic extract of *Dactyloctenium aegyptium* was further subjected to fractionation by column chromatography using n-Hexane (NHF), Chloroform (CF), Ethyl acetate (EAF) and Methanol (MF). All fractions were calculated for their yield and stored in desiccators till further use.

Example 5: Preliminary Phytochemical Screening of different fractions of Ethanolic extract of *Dactyloctenium aegyptium*

All fractions were qualitatively tested for the presence of chemical constituents and these were identified by characteristic colour changes using standard procedure.

Example 6: Study of antidiabetic activity of different fractions of Ethanolic extract of *Dactyloctenium aegyptium*

All fractions were evaluated for their antidiabetic activity in Streptozotocin induced diabetic rats and the same method was followed as mentioned in example 3.



T. G. Subalaxshmi
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

From the results inventors found that Methanolic fraction of Ethanolic extract of *Dactyloctenium aegyptium* is having best antidiabetic activity and hence further studies focused on the isolation of active constituent responsible for activity.

Example 7: Isolation of active constituent from Methanolic fraction of Ethanolic extract of *Dactyloctenium aegyptium*

Based upon the earlier literature, phytochemical screening and TLC profile of Methanolic fraction of Ethanolic extract of *Dactyloctenium aegyptium*, active flavonoid constituent was isolated by preparative TLC technique and it was subjected to characterization by various analytical techniques.

Example 8: Physical Characterization of isolated compound

Colour : Yellow to brown

Physical appearance: Powder

Solubility: Soluble in water

Melting point: 243° C

Example 9: Chemical Characterization of isolated compound


Figure 1: ^1H NMR Spectra of Isolated Compound



T. G. Balakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Figure 2: ^{13}C NMR Spectra of Isolated Compound

M1



T. G. Babu
 PRINCIPAL
 Bapatla College of Pharmacy
 BAPATLA - 522 101.

Figure 3: Mass Spectra of Isolated Compound






Figure 4: IR Spectra of Isolated Compound



T. G. Subashini
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Based on the physical and spectral characterization reports the isolated compound was identified as Rutin.



RUTIN (C₂₇H₃₀O₁₆)

2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl]oxochromen-4-one.

Example 10: Mechanistic studies on Rutin

Rutin was further tested for its antidiabetic activity in Streptozotocin induced diabetic rats at different doses like 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg and 50mg/kg P.O. 50mg/kg P.O was observed as effective antidiabetic dose in rats and upon conversion to Human equivalent dose (HED), dose became 500 mg. Further studies focused on mechanistic studies for Rutin.

Table 1: Effect of Rutin on insulin secretion from perfused pancreas

	Insulin secretion (ng/ml)	
	2.8 mM glucose	11 mM glucose
Control	0.05 ± 0.005	0.82 ± 0.16
Rutin	1.42 ± 0.06 [*]	1.66 ± 0.19 [*]

^{*}P<0.001 compared with 2.8 mM glucose, ^{*}P<0.01 compared with 11 mM glucose.

Table 2: Effect of Rutin on insulin secretion from isolated islets

	Insulin (ng/mg islet protein)	
	3 mM glucose	11 mM glucose
Control	3.35 ± 0.34	6.23 ± 0.78
Rutin	7.12 ± 0.64 [*]	9.98 ± 0.92 [*]

^{*}P<0.01 compared with 3 mM glucose, ^{*}P<0.01 compared with 11 mM glucose.

From the above results inventors found that Rutin is having Insulin Secretagogue property.

Example 11: Solubility and Stability studies for Rutin in different Buffers

Solubility of Rutin was studied in different buffers like HCl Buffer pH 1.2, Phosphate buffer pH 6.8, Acetate buffer pH 4.6 and also in water. Rutin had shown very poor solubility profile in all pH media and also in water. Among these, Rutin shows highest solubility in phosphate buffer pH 6.8 (0.2 mg/ml) whereas Rutin shows lowest solubility in water (0.16 mg/ml).

T. Balakrishna
PRINCIPAL
Bapatia College of Pharmacy
BAPATLA - 522 101.

Further stability of Rutin was studied in HCl Buffer pH 1.2 and Phosphate buffer pH 6.8. Inventors found that Rutin was stable in both HCl Buffer pH 1.2 and Phosphate buffer pH 6.8.

Example 12: Micromeritic Properties of Rutin

Table 3:

Bulk density (g/ml)	Tapped density (g/ml)	Carr's Index (%)	Hausner's ratio	Inference
0.29	0.41	29.26	1.41	Poor flow

Examples 13-15: Preparation of tablets comprising Rutin with different Superdisintegrants

Table 4:

Ingredients	Quantity in mg/tablet		
	Example 13	Example 14	Example 15
Rutin	500	500	500
Povidone	Q.S.	Q.S.	Q.S.
Sodium starch glycolate	30	--	--
Cross Povidone	--	30	--
Cross Carmellose Sodium	--	--	30
Magnesium stearate	3	3	3
Talc	3	3	3
Total weight	536	536	536

Example 16: Physical Properties of Rutin Tablets

Table 5:

Example No.	Theoretical Weight (mg)	Average Weight (mg)	Hardness (kg/cm ²)	% Friability	Disintegration time (min)
Example 13	536	536.8±0.66	5.6±0.22	0.24	09
Example 14	536	538.2±0.88	4.8±0.16	0.32	06
Example 15	536	537.4±0.46	4.2± 0.14	0.52	04

T. G. Lalapasha
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

From the above results, inventors selected example 15 as best formulation.

Example 17: Dissolution studies for Rutin Tablets

Based upon the solubility studies in different buffers, no buffer satisfies the criteria for sink conditions. Hence solubility of Rutin was aided by the addition of different concentrations of surfactants in Phosphate buffer pH 6.8.

Table 6: Solubility of Rutin in Phosphate buffer pH 6.8 with varying concentrations of surfactants

	Amount in 1 ml (mg/ml)
Phosphate buffer pH 6.8	0.223
Phosphate buffer pH 6.8 +0.5% SLS	1.74
Phosphate buffer pH 6.8 +1% SLS	2.47
Phosphate buffer pH 6.8 +1.5% SLS	3.52
Phosphate buffer pH 6.8 + 0.5% Tween 80	1.58
Phosphate buffer pH 6.8 + 1% Tween 80	2.39
Phosphate buffer pH 6.8 + 1.5% Tween 80	2.98

Based upon the above results, Phosphate buffer pH 6.8 +1.5% SLS satisfies the criteria for sink conditions and hence it was selected as dissolution media for example 15.

Table 7: Dissolution studies for Rutin Tablets (Example 15) in Phosphate buffer pH 6.8 +1.5% SLS

S. No.	TIME (min)	% Drug Release
1.	10	32.04
2.	20	68.04
3.	30	88.74
4.	40	99.36



T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

ANNEX B

Title, Details of the invention and the patent application number in case patent has been filed

Intellectual Property India
PATENTS (DESIGNS / TRADE MARKS)
GEOGRAPHICAL INDICATIONS

GOVERNMENT OF INDIA

Controller General of Patents, Designs and Trademarks
Department of Industrial Policy and Promotion
Ministry of Commerce and Industry

Application Details

APPLICATION NUMBER	201540214417
APPLICATION TYPE	ORDINARY APPLICATION
DATE OF FILING	26/04/2015
APPLICANT NAME	DR. TRILAKSHI ISWARA GOPALA KRISHNA MURTHY
TITLE OF INVENTION	PHARMACEUTICAL COMPOSITIONS COMPRISING RUTIN ISOLATED FROM DACTYLOCTENIUM AEGYPTIUM
FIELD OF INVENTION	CHEMICAL
E-MAIL (AS PER RECORD)	
ADDITIONAL E-MAIL (As Per Record)	gop.pri@gmail.com
E-MAIL (UPDATED Online)	
PRIORITY DATE	
REQUEST FOR EXAMINATION DATE	01/01/2016
PUBLICATION DATE (U/S 11A)	23/10/2017
FIRST EXAMINATION REPORT DATE	15/12/2019
REPLY TO FER DATE	15/06/2020

JCC Form.doc
ABS agreement.doc



T. Gopalakrishna
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

ANNEX - C

Authorisation made by the Applicant (*if any*) for signing the Agreement and/or filing IPR

Answer: --- Not Applicable ---

T. Gopalabachari
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



ANNEX - D

Name of the countries/territories where IPR over the invention is sought to be taken

Answer: India

T. Gopalakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.




PERMIT OR ITS EQUIVALENT CONSTITUTING AN INTERNATIONALLY RECOGNIZED CERTIFICATE OF COMPLIANCE (IRCC)

Internationally Recognised Certificate of Compliance (IRCC) is a globally recognised compliance certificate that serves as an evidence of the decision by the Parties to grant permit to the Applicant. The permit issued by the National Biodiversity Authority (*the competent national authority under the Nagoya Protocol*) will facilitate generation of IRCC and will be published online in the Access and Benefit Sharing Clearing House (ABSCH) (<https://absch.cbd.int/>)

By procuring an IRCC, the Applicant can globally demonstrate their legal compliance with the domestic Access and Benefit Sharing (ABS) legislation (in the present case with the Biological Diversity Act, 2002 and Rules, 2004). Applicant can also keep certain information confidential, as the IRCC document is publicly available. For this purpose, the Applicant shall fill in the following details as given in the table below:

S.No	Particulars	Details about the nature of information (Please mention YES or NO in the box)
1	Name of the Applicant: Dr. Talasila E Gopala Krishna Murthy	Do you require your name to be kept confidential? No
2	Subject matter of approval: Pharmaceutical compositions comprising rutin isolated from Dactyloctenium aegyptium	Do you require the biological resources/knowledge for which the approval was given to be kept confidential? Yes
3	Keywords that describe the subject matter of approval: Rutin, Dactyloctenium aegyptium	Do you require the keywords that describes or indicates the biological resources/knowledge for which the approval was given to be kept confidential? No
4	Type of activity to be undertaken using the subject matter of approval: Anti-Diabetic Activity	Do you require the activity (research/commercial utilisation/bio-survey and bio-utilisation/IPR/transfer of biological resources/knowledge) to be carried out using the approved biological resources/knowledge to be kept confidential? Yes




Applicants Signature
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Disclaimer: Please note that the above format does not constitute an access permit in itself and only validates the permit.



National Biodiversity Authority
 राष्ट्रीय जैव विविधता प्राधिकरण
 (Statutory body of Ministry of Environment, Forest and Climate Change, Government of India)



J. Justin Mohan, IFS
 Secretary

+91 44 2254 1071

+91 44 2254 1074

secretary@nba.nic.in @ www.nbaindia.org

5th Floor, CSIR Road, TICEL Bio Park,
 Taramani, Chennai - 600 113, Tamil Nadu, India.

5 वा तल, सीएसआईआर रोड, टाइकल बायो पार्क,
 तारामनि, चेन्नई - 600113 तमिळुनाडु, भारत.

NBA/IPR Appl/3880/20-21/ 340

23.11.2020

To

Dr. Talasila E Gopala Krishna Murthy,
 Bapatla College of Pharmacy, GBC Road,
 Bapatla, Andhra Pradesh -522101.

Email: bcp.principal@gmail.com, indira.sarihaddula@gmail.com,
 moparthijesumercy01@gmail.com

Madam,

Sub: Approval for applying for IPR as per Section 6 of the Biological Diversity Act,
 2002 read with Rules 18 of the Biological Diversity Rules, 2004 – reg.


Ref: Application in Form-III No. 3880

With reference to your application cited in reference on the subject cited above to facilitate for the invention titled "**Pharmaceutical compositions comprising okra mucilage and neem leaf extract**" using the biological resource *Neem leaves and Okra* has been approved by the National Biodiversity Authority subject to the conditions laid down namely in the agreement.

In this regard, I am enclosing herewith one mutually signed stamp paper agreement executed between National Biodiversity Authority and the applicant for the applicant's reference and compliance. It is also to inform you that breach of the terms of agreement and provisions of the Biological Diversity Act, 2002 and Biological Diversity Rules, 2004 made thereunder will invite imposition of penalties as per Section 55, 56 & 57 of the Biological Diversity Act, 2002.

Please acknowledge receipt of this communication.

Yours faithfully,


 (J. Justin Mohan)
 Secretary, NBA

Encl.: As above.

Copy to:

Member Secretary, Andhra Pradesh Biodiversity Board, Flat No.210 Walnut Block,
 Raintree Park, Nagarjuna Nagar, Opp. Nagarjuna University, NH-5, Guntur District,
 Andhra Pradesh – 522508

Ms. Sarihaddula Indira, No 21/485-4B. Lakshmanaraopuram, Machilipatnam,
 Krishna, Andhra Pradesh - 521001

Ms. Moparthi Jesu Mercy, Srungarapuram, Bapatla, Guntur, Andhra Pradesh -
 522101

भारतीय गैर न्यायिक

बीस रुपये

रु.20



Rs.20

TWENTY
RUPEES

INDIA NON JUDICIAL

ఆంధ్రప్రదేశ్ ఆంధ్ర ప్రదేశ్ ANDHRA PRADESH

SL No. 5377 Date 05-09-2020

Sold to: T. Gopalakrishna Murthy, having address at Bapatla College of Pharmacy, GBC Road, Bapatla, Andhra Pradesh -522101, 2.Ms.Sarihaddula Indira having address at No.21/485-4B, Lakshmanaraopuram, Machilipatnam, Krishna, Andhra Pradesh -521001 and 3.Ms.Moparti Jesu Mercy having address at Srungarapuram, Bapatla, Guntur Andhra Pradesh-522101 who are citizens of India. Hereafter the Applicants.

For Whom: AGREEMENT FOR ACCESS AND BENEFIT SHARING

72AA 767860

DAMMU RAJESWARA RAO

Licensed Stamp Vendor

L.No.07-20-010/2013

S.L.No.07-20-004/2020 To 31-12-2022

D.No. 11-7-B, Kalidas Street, Bapatla

Guntur Dt. A.P. Pin No-522101

MS-655033944

(Form-III - For filing applications for obtaining any Intellectual Property Right)

(Under the Biological Diversity Act, 2002 and Rules, 2004 and Guidelines on ABS Regulations, 2014)

This Agreement is made and entered on this 5th day of September, 2020 at Chennai, India.

Between

National Biodiversity Authority, a statutory body established under the Biological Diversity Act, 2002, having its head office at 5th Floor, TICEL Bio Park, Taramani, Chennai-600 113, Tamil Nadu, India (hereafter "NBA"), acting through and represented by the Secretary, NBA/authorized signatory of NBA, being the person authorised to execute this Agreement.

And

1. Dr. Talasila E Gopala Krishna Murthy, having address at Bapatla College of Pharmacy, GBC Road, Bapatla, Andhra Pradesh -522101, 2.Ms.Sarihaddula Indira having address at No.21/485-4B, Lakshmanaraopuram, Machilipatnam, Krishna, Andhra Pradesh -521001 and 3.Ms.Moparti Jesu Mercy having address at Srungarapuram, Bapatla, Guntur Andhra Pradesh-522101 who are citizens of India. Hereafter the Applicants.

Hereafter, referred to as the "Parties" and individually as a "Party".

T. Gopalakrishna

PRINCIPAL

Bapatla College of Pharmacy
BAPATLA - 522 101,

WHEREAS the NBA is the authority established under the Biological Diversity Act, 2002 (hereafter "the Act") authorised to grant approval for the purpose set forth herein and to determine terms and conditions to secure fair and equitable sharing of benefits arising out of the use of biological resources, knowledge and practices associated with their use;

WHEREAS the Applicant has submitted an application in Form III (Appl.no.3880) dated 02.03.2020 under the Biological Diversity Rules, 2004 (hereafter the "Rules, 2004") to seek prior approval from NBA;

WHEREAS under the Rules and the guidelines on access to biological resources and/or associated knowledge and benefit sharing regulations, 2014 made under the Act, the approval shall be in the form of a written agreement duly executed between the Parties (hereafter the "Agreement");

AND the Parties have entered into this Agreement for access and benefit sharing according to the terms and conditions set out below.

NOW the Parties agree as follows:

1. Definition

For the purpose of this Agreement, the expression "Effective Date" shall mean the date on which both the parties sign this Agreement. In case the parties sign on different dates, the effective date shall be the date signed by NBA;

2. Terms and Conditions of the Agreement

2.1 Grant of approval

The NBA hereby grants approval for filing applications for obtaining Intellectual Property Right ("IPR") over the invention as described in Annex B, only in the countries mentioned in Annex D subject to such other terms and conditions set forth in this Agreement.


2.2 Scope and extent


The approval is limited to the extent and for the purpose for which it is accorded under the appropriate Annexures.

2.3 Period

2.3.1 *Period of Agreement* - This Agreement shall remain in force from the effective date of this Agreement till the subsistence of the IPR for which approval was granted.

2.3.2 Notwithstanding the above, this Agreement shall remain in force until the applicant fulfils all the obligations as required under this Agreement.




PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

2.4 Transfer to third party or by operation of law

In the event that the IPR of the Applicants is transferred by way of an assignment, licensing or by operation of law (including in cases of death or bankruptcy or dissolution of a company), all rights and obligations under this Agreement shall be binding upon the assignee or licensee or legal representative or the person to whom the IPR devolves as the case may be.

In the case of above eventuality, the legal representative or the assignee or licensee or the person to whom the IPR has devolved shall intimate and submit such relevant documents to NBA within **sixty days** of the happening of such event. Upon receiving such intimation, NBA may amend the agreement under clause 13 of this Agreement so as to ensure fair and equitable benefit sharing.

3. Obligations of the Applicants

3.1 The Applicants shall share benefits as stipulated under Schedule A.

3.2 The permission granted to the Applicants is limited to that granted by the NBA in Annex-B of Schedule B of this Agreement. All other activities of the Applicants which require NBA's prior approval will need to be applied separately in the concerned Form under Rules, 2004. Further, the Applicants shall intimate to the NBA in the event of seeking IPR in other territories and thereafter the Agreement's annex will be suitably amended.

3.3 The Applicants shall abide by all the terms and conditions of the Agreement and other related legislations in force including any clearances required from the concerned authorities, such as the Chief Wildlife Warden in protected areas and forest authorities in other forest areas.

3.4 The Applicants shall, in the event that the Applicants form a body corporate, association or organization under section 3(2)(c), intimate the same and submit all the related documents to NBA within 90 days from the completion of that event. Subsequent to the said intimation, NBA shall decide whether this Agreement shall be amended as per clause 13 or a fresh approval is required. NBA's decision in this regard shall be final.

3.5 The Applicants shall have India as its first source of supply and/or cultivation of biological resources for the commercialization of IPR as the case may be.

3.6 The Applicants shall in the event of any breach of this Agreement pay such compensation commensurate with the damage incurred to the Republic of India or to the benefit claimers as decided by the appropriate forum.



T. Gokulaprasad
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

- 3.7 The Applicants shall keep all the relevant records that serve as a proof of the monetary benefits shared by the Applicants with NBA or the concerned benefit claimers as the case may be, together with supporting documents. This may be submitted to NBA as specified from time to time and such records shall be retained for at least three (3) years after the termination of this Agreement.
- 3.8 NBA shall have the right to regulate /monitor the activities approved under this Agreement, by itself or through any appropriate agency as it may deem fit.
- 3.9 Whenever the Applicants require to access biological resources for commercial utilization of the IPR for which approval is granted under this Agreement, the Applicants shall take prior approval of NBA under Form I of the Rules, 2004 or the respective form of the concerned State biodiversity rules.
- 3.10 The Applicants shall notify in writing to the NBA about the grant of IPR and the assignment or licensing of such IPR, if any, in each of the countries/territories as specified in Annex D, within 60 days from the date of grant of the said IPR.
- 3.11 The Applicants shall, in case of any modification or improvement or commercialization of the invention/ product/process of the IPR, intimate to NBA within 45 days of the happening of such event. Based on such intimation, NBA may decide to review the earlier approval and its decision shall be final.
- 3.12 The Applicants, in the event of decision to withdraw or abandon the patent application, shall intimate to NBA within 45 days of the happening of such event.

3.13 Status Reports

3.13.1 The Applicants shall submit a status report for each reporting year not later than two months of the end of each reporting year in the prescribed format of NBA.

3.13.2 During the subsistence of this Agreement, the Applicants shall submit separate status reports in relation to each of the countries/territories mentioned in Annex D for each reporting year in the prescribed format of NBA. This shall be submitted not later two months of the end of each reporting year.

3.13.3 Non-submission of the status reports within the stipulated time period in relation to any of the countries/territories mentioned in Annex D will be construed as a breach for which penalty may be imposed by NBA under clause 6 of this Agreement.



T. G. Subramanian
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

3.13.4 The Applicants shall submit a copy of Form 27 of the Indian Patent Rules, 2015 within one month of submitting the same to the Patent Office.

4. Fair and Equitable Benefit Sharing

- 4.1 The Applicants shall share benefits as per Schedule A in monetary mode.
- 4.2 The Applicants shall make the payment preferably by way of demand draft or any other approved mode of payment and the same shall be drawn in the name of "National Biodiversity Fund".

5. Written Notice

- 5.1 Any communication including serving notices under this Agreement, shall be in writing and communicated by Registered post with acknowledgement due or e-mail or fax in the address mentioned hereunder.

If to NBA:

The Secretary, NBA, 5th Floor, TICEL Bio Park, Taramani, Chennai-600 113, Tamil Nadu, India. secretary@nba.nic.in

If to the Applicants:

1. Dr. Talasila E Gopala Krishna Murthy, Bapatla College of Pharmacy, GBC Road, Bapatla, Andhra Pradesh -522101. Email: bcp.principal@gmail.com
2. Ms.SarihaddulaIndira,No.21/485-4B,Lakshmanaraopuram,Machilipatnam Krishna, Andhra Pradesh -521001. Email: indira.sarihaddula@gmail.com
3. Ms.Moparti JesuMercy,Srungarapuram, Bapatla, Guntur, Andhra Pradesh-522101. Email:moparthijesumercy01@gmail.com

- 5.2 Notice is deemed to have been given if duly communicated in accordance with the Indian Contract Act, 1872 and the Information Technology Act, 2000 and related Indian legislations.

- 5.3 Any change in the address/email address/fax of the Parties shall be notified to the other Party within 15 days of such change by way of a notice.

6. Procedure for imposing penalty in case of breach.

- 6.1 If NBA has prima facie evidence to the effect that the Applicants have committed a breach of any of the terms of this Agreement, NBA shall send a written notice to the Applicants communicating the default or details of the breach within 30 days of the discovery of that event, giving an opportunity to be heard to the Applicants.




T. Gokulabharathi
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101

- 6.2 The Applicants shall within 30 days from the date of serving of such notice respond in writing to NBA.
- 6.3 Upon receiving such explanation from the Applicants, NBA shall take into account the explanation and decide if there is a breach committed by Applicants or not. In the event that the NBA does not receive such explanation from the Applicants, NBA shall send final notice to the Applicants. If the Applicants respond within 30 days, NBA shall be taken into account the explanation and decide on the breach. If the Applicants do not respond within 30 days, the Applicants will be deemed to be in breach of this Agreement.
- 6.4 In the event that the Applicants do not respond to the final opportunity given by NBA or in the event that NBA decides that there is a breach of this Agreement, NBA has the power to issue any order executable under section 53 of the Act including imposition of penalty of a sum which may extend to one lakh rupees as determined by NBA from time to time and in addition direct the Applicants to pay such compensation commensurate with the damage incurred by the Republic of India or the benefit claimers.
- 6.5 Penalties imposed by NBA under this clause shall be in addition to any recovery of any monetary benefits due, compliance with directions or orders issued by NBA and without prejudice to any other rights under this Agreement.
- 6.6 Notwithstanding any of the clauses above, in addition to imposition of penalty, if the breach or default committed by the Applicants amounts to violation of any of the provisions of the Act, appropriate legal proceedings shall be initiated under Section 61 of the Act.

7. Termination and Revocation

- 7.1 Subject to clause 2.3, the Agreement shall stand automatically terminated on the completion of the period agreed to between the Parties including the period of extension agreed to, if any. On termination, the Applicants shall comply with obligation under clause 7.3.
- 7.2 During the subsistence of this Agreement, the Applicants shall have an option to initiate termination of this Agreement by sending a request to NBA in the form of a notice stating valid reasons for the same. On receipt of the same, it shall be the discretion of NBA to accept the reasons specified by the Applicants or not. In the event of its decision to terminate, NBA shall intimate to the applicants by way of a notice within 90 days of making the decision. On receipt of such a notice from NBA, the applicants shall comply with clause 8.3.
- 7.3 Upon termination of the Agreement, the Applicants shall pay all outstanding dues including the benefit sharing amount and submit status report dues, if any, due until then by the Applicants within 45 days of the date of termination of this Agreement.




T. J. Balakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

- 7.4 NBA may withdraw the approval granted and revoke this Agreement in case of occurrence of any of the conditions mentioned in Rule 15 of the Rules, 2004 or if the applicant performs activities contrary to any restriction or prohibition imposed by NBA or under the Act and Rules, 2004.


8. Liabilities and Indemnification

- 8.1 NBA shall not be liable for any loss or damage whatsoever caused to the Applicants due to revocation of approval for access and/or termination of this Agreement on any grounds whatsoever.
- 8.2 The Applicants shall be jointly and severally responsible for any claims by third parties arising from the Applicants acts or omissions in the course of performing this Agreement and under no circumstances shall the NBA be held responsible or liable for any claims by such third parties.
- 8.3 The Applicants shall pay such sum for breach committed by the Applicants as determined by NBA under clause 6 of this Agreement which is in addition to the compensation commensurate with the damage incurred by the Republic of India or the benefit claimers that the Applicants are liable to pay as decided by the appropriate forum.
- 8.4 The Applicants shall indemnify and save NBA and its employees, members and officers, from and against all claims, demands, losses, damages, costs (including attorney fees), actions, suits or other proceedings, all in any manner based upon, arising out of, related to, occasioned by or attributable to, any acts or conduct of the Applicants, its employees or agents, (whether by reason of negligence or otherwise) in the performance by or on behalf of the Applicants of the provisions of this Agreement or any activity undertaken or purported to be undertaken under the authority or pursuant to the terms of this Agreement.



9. Confidentiality

- 9.1 Upon request from the Applicants, NBA shall keep as confidential those information which is desired to be kept as confidential by the Applicants.
- 9.2 Notwithstanding the above, confidential information may be disclosed by NBA to the extent required by any law or regulation or order of any authority established by law having jurisdiction over any of the Parties or in the opinion of NBA such disclosure becomes necessary to deal with any emergency situations, or national or public interest.



PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

10. Arbitration


- 10.1 In case any dispute or difference arises out of the interpretation of any clauses of the Agreement, either of the Parties may give the other Party a notice clearly identifying and providing details of the dispute. On receipt of such notice by the other Party, the Parties shall try to settle such dispute/difference amicably between them by negotiating in good faith within 30 days of the receipt of such notice.
- 10.2 If the dispute or difference is not resolved by such negotiations within the period mentioned, the dispute or difference shall be referred to the sole arbitrator appointed by NBA.
- 10.3 The arbitration shall be governed by the Arbitration and Conciliation Act, 1996 and the rules framed thereunder. The place of arbitration shall be Chennai, India.
- 10.4 The award of the Arbitrator shall be final, conclusive and binding on the Parties. The Arbitrator shall be competent to decide whether any matter or dispute or difference referred to him falls within the purview of arbitration.

11. Governing Law and Jurisdiction

- 11.1 This Agreement is governed by and is to be construed in accordance with the laws of India without regard to the principles of conflicts of laws subject to the provisions of arbitration clauses to this Agreement.
- 11.2 In the event of a dispute or difference not settled through arbitration as specified in clause 11, the Parties shall irrevocably and unconditionally submit to the appropriate court of jurisdiction in Chennai.
- 11.3 As regards all other aspects and the terms and conditions not provided for this in this Agreement, they shall be governed by the provisions of the Act read with Rules and Regulations made thereunder.
- 11.4 This Agreement shall not in any way constitute or be presumed to constitute a partnership or a joint venture or a joint enterprise in any way or for any purpose between the Parties hereto or make the parties in any way liable as partners of or as agents for one another.

12. Severability

- 12.1 If any part of this Agreement is declared or held improper or unjustifiable or invalid by a Court of Law for any reason, the deficiency or invalidity of that part shall not affect the validity of the remainder which will continue in full force and effect and be construed as if the Agreement had been executed without the invalid portion.
- 12.2 However the remainder of the Agreement shall not come into force unless the remainder is consistent with the declaration or order or judgment of the Court.



T. Subalaxshmi
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101

13. Amendment

No amendment to this Agreement shall be valid or binding upon the Parties, unless agreed upon by the Parties, in writing, and signed on behalf of each Party by their duly and legally authorized persons and such amendment shall be made as a supplementary agreement along with Annexes, as applicable.


14. Entirety of Agreement

This Agreement constitutes the culmination of all prior negotiations, understanding, representations and commitments and sets down the complete terms and conditions of Agreement between the parties as to the subject matter.

15. Annex and Schedules

- a. The Schedules and their Annexes attached to this Agreement or Schedule that may be added subsequently by way of an amendment under the provisions of this Agreement shall form an integral part of this Agreement and shall be binding on the Parties.
- b. This Agreement has been executed in duplicate, each of which shall be deemed to be original; one shall be retained by the NBA and other by the Applicant and both shall constitute one and the same instrument.

IN WITNESS WHEREOF the parties hereto have signed in this Agreement on the day month and the year aforesaid in this Agreement.



Signed by the Authorized person of the Authority

For National Biodiversity Authority

Witnesses

1. Signature

Name

Address

Dr. K. Chitrarasu
Technical Officer (B)
National Biodiversity Authority
Government of India
5th Floor, TICEL Bio Park,
CSIR Road, Taramani, Chennai- 600 113

2. Signature

Name

Address

K. CHITRARASU
Advisor (Law)
National Biodiversity Authority,
Govt. of India
TICEL Bio Park, 5th Floor,
CSIR Road, Taramani,
Chennai - 600 113.

T. Gubalaprasanna
(s/d with date)

Signed by the Applicants
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.
For the Applicant

Witnesses

1. Signature

Name: Y. Sushma

Address: Assistant
Professor, Bapatla College of
Pharmacy, Bapatla-522101

2. Signature

Name: T. Vijay Sekhar

Address: Jr. Assistant,
Bapatla College of Pharmacy,
Bapatla-522101

SCHEDULE A – BENEFIT SHARING COMPONENT

Higher benefit sharing component is fixed, due to use of traditional knowledge in the invention

- (i) Where the applicant himself commercializes the process/product/innovation, the monetary benefit sharing shall be 0.4% on the annual gross ex-factory sale minus government taxes.
- (ii) Where the applicant assigns/licenses the process/product/innovation to a third party for commercialization, the applicant shall pay to NBA 4.0% of the fee received (in any form including the license/assignee fee) and 4.0% of the royalty amount received annually from the assignee/licensee.

SCHEDULE B – ANNEXES TO BE ATTACHED

ANNEX A - Details of biological resources and/or knowledge associated thereto and geographical locations

ANNEX B - Title, Details of the invention and the patent application number in case patent has been filed

ANNEX C - Authorisation made by the Applicant (*if any*) for signing the Agreement and/or filing IPR

ANNEX D - Name of the countries/territories where IPR over the invention is sought to be taken

T. Goblapusha
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



ANNEXURE - A

Details of biological resources and/or knowledge associated thereto and geographical locations

Neem leaf were collected from the neem trees available at our college campus. Okra was purchased from local market as it is commonly used vegetable.

GEO-LOCATION OF ACCESS - BAPATLA, GUNTUR, ANDRA PRADESH

T. Girela Joushan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



ANNEXURE - B

Title, details of the invention and the patent application number in case patent has been filed

Answer: Neem Leaf extract was prepared and concentrated to obtain a semi solid. Okra mucilage was also prepared and dried to get a solid powder. Damp mass of neem leaf extract was prepared by mixing okra mucilage. The damp mass was sieved through sixteen mesh screen and dried. The Dried granules were filled into capsules.

The Invention was not yet filed for patent. It is in process.

T. Gopalakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



ANNEX - C

Authorisation made by the Applicant (*if any*) for signing the Agreement and/or filing IPR

Answer: --- Not Applicable ---

T. Jilalabashin
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



AUTHORISATION LETTER FOR REPRESENTATIVE

We Ms. Sarihaddula Indira, Moparthi Jesumercy & Dr. T. E. Gopala Krishna Murthy hereby authorize Mr. Dr. T. E. Gopala Krishna Murthy as our representative to submit an application under Form III of the Biological Diversity Rules, 2004, to the National Biodiversity Authority, India (hereinafter referred to as the NBA) for the purpose of obtaining the prior approval as required under the Biological Diversity Act, 2002, for access to biological resources/ knowledge associated with biological resources and/or traditional knowledge/transfer of results of research based on biological resources/application for an IPR/third party transfer of accessed biological resources.*

We hereby authorize and declare that all actions committed by the representative with regard to the above purpose and all communications by the representative with the NBA in this regard shall bind us entirely.

1. *Indira*
2. *M. Jesumercy*
3. *T. Gopalakrishna*

Signature of Applicants
(Common seal if applicable)

Date : 13-11-2020
Station: Bapatla

T. Gopalakrishna
Signature of Representative
(Common seal if applicable)

PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Date : 13-11-2020
Station: Bapatla



ANNEX - D

Name of the countries/territories where IPR over the invention is sought to be taken

Answer: India

T. Subalakrishnan
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.



PERMIT OR ITS EQUIVALENT CONSTITUTING AN INTERNATIONALLY RECOGNIZED CERTIFICATE OF COMPLIANCE (IRCC)

Internationally Recognised Certificate of Compliance (IRCC) is a globally recognised compliance certificate that serves as an evidence of the decision by the Parties to grant permit to the Applicant. The permit issued by the National Biodiversity Authority (the competent national authority under the Nagoya Protocol) will facilitate generation of IRCC and will be published online in the Access and Benefit Sharing Clearing House (ABSCH) (<https://absch.cbd.int/>)

By procuring an IRCC, the Applicant can globally demonstrate their legal compliance with the domestic Access and Benefit Sharing (ABS) legislation (in the present case with the Biological Diversity Act, 2002 and Rules, 2004). Applicant can also keep certain information confidential, as the IRCC document is publicly available. For this purpose, the Applicant shall fill in the following details as given in the table below:

S.No	Particulars	Details about the nature of information (Please mention YES or NO in the box)
1	Name of the Applicant: Dr. T. E. Gopala Krishna Murthy	Do you require your name to be kept confidential? No
2	Subject matter of approval: Pharmaceutical compositions comprising okra mucilage and neem leaf extract	Do you require the biological resources/knowledge for which the approval was given to be kept confidential? Yes
3	Keywords that describe the subject matter of approval: neem leaf, Okra mucilage	Do you require the keywords that describes or indicates the biological resources/ knowledge for which the approval was given to be kept confidential? No
4	Type of activity to be undertaken using the subject matter of approval: Anti-Diabetic Activity	Do you require the activity (research/commercial utilisation/bio-survey and bio-utilisation/IPR/transfer of biological resources/knowledge) to be carried out using the approved biological resources/knowledge to be kept confidential? Yes



T. Gopalakrishnan
Applicants Signature
PRINCIPAL
Bapatla College of Pharmacy
BAPATLA - 522 101.

Disclaimer: Please note that the above format does not constitute an access permit in itself and only validates the permit.



**INTELLECTUAL
PROPERTY INDIA**

PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS



सत्यमेव जयते

भारत सरकार
GOVERNMENT OF INDIA

पेटेंट कार्यालय
THE PATENT OFFICE

पेटेंट प्रमाणपत्र
PATENT CERTIFICATE
(Rule 74 Of The Patents Rules)

क्रमांक : 044135346
SL No :



पेटेंट सं. / Patent No. : 380979
आवेदन सं. / Application No. : 4504/CHE/2014
फाइल करने की तारीख / Date of Filing : 16/09/2014
पेटेंटी / Patentee : TALASILA ESWARA GOPALA KRISHNA MURTHY

प्रमाणित किया जाता है कि पेटेंटी को उपरोक्त आवेदन में यथाप्रकटित STATIN IMPREGNATED COLLAGEN BASED DERMAL SCAFFOLDS MADE OF COW URINE नामक आविष्कार के लिए, पेटेंट अधिनियम, 1970 के उपबंधों के अनुसार आज तारीख 16th day of September 2014 से बीस वर्ष की अवधि के लिए पेटेंट अनुदत्त किया गया है।

It is hereby certified that a patent has been granted to the patentee for an invention entitled STATIN IMPREGNATED COLLAGEN BASED DERMAL SCAFFOLDS MADE OF COW URINE as disclosed in the above mentioned application for the term of 20 years from the 16th day of September 2014 in accordance with the provisions of the Patents Act, 1970.



T. Subalakrishna
PRINCIPAL
Bapatla College of Pharmacy
Bapatla 522 101

अनुदान की तारीख : 30/10/2021
Date of Grant :

[Signature]
पेटेंट नियंत्रक
Controller of Patent

टिप्पणी - इस पेटेंट के नवीकरण के लिए फीस, यदि इसे बनाए रखा जाना है, 16th day of September 2016 को और उसके पश्चात प्रत्येक वर्ष में उसी दिन देय होगी।
Note - The fees for renewal of this patent, if it is to be maintained will fall / has fallen due on 16th day of September 2016 and on the same day in every year thereafter.

PATENT OFFICE
INTELLECTUAL PROPERTY BUILDING
G.S.T. Road, Guindy, Chennai-600032
Tel No. (091)(044) 22502081-84 Fax No. 044 22502066
E-mail : Chennai-patent@nic.in
Web Site : www.ipindia.gov.in



सत्यमेव जयते

GOVERNMENT OF INDIA



INTELLECTUAL
PROPERTY INDIA
PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS

Date/Time : 17/11/2022

Agent Number:

CHALLAN : TR-5

DOCKET NO:111997

To,

TALASILA ESWARA GOPALA KRISHNA MURTHY

BAPATLA COLLEGE OF PHARMACY, BAPATLA, GUNTUR DISTRICT, ANDHRA PRADESH - 522101.

bcp.principal@gmail.com

Sr. No.	CBR No.	Reference Number /Application Type	Application Number	Title/Remarks	Amount Paid
1	46370	ORDINARY APPLICATION	202241065915	PHARMACEUTICAL COMPOSITIONS COMPRISING METHANOLIC FRACTION OF ETHANOLIC EXTRACT OF DACTYLOCTENIUM AE	1750
2		E-101/19445/2022-CHE	202241065915	Correspondence	0
3		E-2/4869/2022-CHE	202241065915	Form2	0
		E-5/4712/2022-CHE	202241065915	Form5	0
Total :					1750

Received a sum of Rs. 1750 (Rupees One Thousand Seven Hundred & Fifty only) through

Payment Mode	Bank Name	Cheque/Draft Number	Cheque/Draft Date	Amount in Rs
Draft	State Bank of India	681418	14/11/2022	1750

Note: This is electronically generated receipt hence no signature required.

T. G. Subrahmanya

PRINCIPAL
Bapatla College of Pharmacy
Bapatla 522 101

PATENT OFFICE
INTELLECTUAL PROPERTY BUILDING
G.S.T. Road, Guindy, Chennai-600032
Tel No. (091)(044) 22502081-84 Fax No. 044 22502066
E-mail : Chennai-patent@nic.in
Web Site : www.ipindia.gov.in



CHALLAN : TR-5
DOCKET NO:127309

Date/Time : 29/12/2022

Agent Number:

To,
DR. TALASILA ESWARA GOPALA KRISHNA MURTHY
BAPATLA COLLEGE OF PHARMACY, BAPATLA - 522101, GUNTUR DISTRICT, ANDHRA PRADESH, INDIA.
bcp.principal@gmail.com

Sr. No.	CBR No.	Reference Number / Application Type	Application Number	Title/Remarks	Amount Paid
1	53479	ORDINARY APPLICATION	202241076750	PHARMACEUTICAL COMPOSITIONS COMPRISING OKRA MUCILAGE AND NEEM LEAF EXTRACT	1750
2		E-101/22942/2022-CHE	202241076750	Correspondence	0
3		E-2/5668/2022-CHE	202241076750	Form2	0
4		E-3/40741/2022-CHE	202241076750	Form3	0
5		E-5/5354/2022-CHE	202241076750	Form5	0
6	53479	R20224047451	202241076750	Form18	4400
		E-106/8364/2022-CHE	202241076750	Form28	0
8		E-101/22943/2022-CHE	202241076750	Others(EDUCATIONAL INSTITUTIONAL ELIGIBILITY DOCUMENT)	0
Total :					6150

Received a sum of Rs. 6150 (Rupees Six Thousand One Hundred & Fifty only) through

Payment Mode	Bank Name	Cheque/Draft Number	Cheque/Draft Date	Amount in Rs
Draft	State Bank of India	681645	27/12/2022	6150

Note: This is electronically generated receipt hence no signature required.


PRINCIPAL
Bapatla College of Pharmacy
Bapatla 522 101



తెలంగాణ తెలంగాణ TELANGANA

AA 540794

SL.No.2174. Date.29-07-2020. R/o. HYD.
Sold to. S.DURGA PRASAD.
S/o. S.VENKATESWARARAO.
For Whom : NATCO PHARMA LIMITED.

KURNOOL NOORJAHAN
LICENSED STAMP VENDOR
L.NO.16-11-018/2012,
Ren.No.16-11-15/2018,
6-3-354/19,Road No:1,Banjara Hills,
Hyderabad (South) T.S. Cell:9391535407.


MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding (hereinafter referred to as "MOU") is made on 2nd day of January, 2021 (hereinafter referred to as "Effective Date") by and between;

M/S NATCO PHARMA LIMITED (CIN: L24230TG1981PLC003201), having its registered office at Natco House, Road No. 2, Banjara Hills, Hyderabad - 500034, Telangana, India, represented by its Vice President (HR & OD), **Mr. Lakshminarayana A.** (hereinafter called "NATCO") which expression shall unless repugnant to the context thereof be deemed to mean and include its permitted assigns and successors) of the First Part

AND

BAPATLA COLLEGE OF PHARMACY, G.B.C. Road, Mahatmajipuram, Bapatla Post Office, Guntur District, Andhra Pradesh, represented by the **Secretary, Bapatla Education Society**, (hereinafter called **BCOP**) which expression shall unless repugnant to the context thereof be deemed to mean and include its permitted assigns and successors) of the Second Part


SECRETARY
BAPATLA EDUCATION SOCIETY
BAPATLA






This **MOU** specifies a framework of co-operation and collaboration between **NATCO** and **BCOP** for exchanging knowledge and facilities for mutual development and benefit.


SCOPE OF COLLABORATION:

1. Objectives: To take up the following activities for mutual benefit
 - 1.1 To initiate exchange of knowledge between NATCO and BCOP.
 - 1.2 To organize Industrial Training Programs to the staff & students of BCOP.
 - 1.3 To collaborate in research and development projects involving staff and students of NATCO and BCOP for which BCOP in advance will have to intimate concerned plant head(s) for the permission and indicate the number of students / staff for such visits.
 - 1.4 To provide short term internship, if any, for students of BCOP.
 - 1.5 To engage students in development work involving them in short term projects.
 - 1.6 Any other activity with mutual agreement.
2. **Responsibilities of BCOP**
 - 2.1 To depute faculty members for collaborative work to be carried out at NATCO
 - 2.2 To depute students both of B. Pharmacy and M. Pharmacy for Industrial tour for which BCOP in advance will have to intimate concerned plant heads for the permission and indicate the number of students / staff for such visits.
 - 2.3 To depute faculty members for training and coaching to be carried out at NATCO, HYDERABAD.
 - 2.4 To maintain the secrecy of the data of NATCO shared for the purpose of research and/or projects.
 - 2.5 To fulfill the assignment/basic research work requested by NATCO.
 - 2.6 The students / staff will not cause any damage to equipment, lab, infrastructure and will not cause any inconvenience to the working conditions of employees at NATCO.

3. Responsibilities of NATCO

- 3.1 To facilitate the use of resources of NATCO in research and development projects, or whatever is required.


SECRETARY
BAPATLA EDUCATION SOCIETY
BAPATLA






- 3.2 Depute Employees for Programs/collaborative research to be carried out at BCOP and NATCO jointly and such projects can be applied for funding offered by government organizations.
- 3.3 To provide projects, if any, to students either to carry them out at BCOP or at NATCO.
- 3.4 To provide Guest lectures on a regular basis, as and when required with prior approval.
- 3.5 Audit the facility of BCOP and help in fixing the gaps and improvements.
- 3.6 To provide Internship to second year M. Pharmacy students to carry on their project work in Formulation R&D, Analytical R&D, provide a guide and to give consent to publish the same article in a reputed journal.
- 3.7 To offer jobs to the M. Pharmacy students after their course completion in BCOP when vacancy arises and their performance meets the criteria at NATCO.
- 3.8 To provide gratis samples of drugs and excipients required for the research work which are not confidential in nature.

4. Liabilities

- 4.1 Each party shall be responsible for its own acts and omissions and the results thereof and shall not be responsible for the acts of the other party and the results thereof.
- 4.2 NATCO shall be indemnified by BCOP for any loss / damage caused to it by the students / staff.

5. Other Terms

- 5.1 The MOU shall be effective on the effective date i.e., from 02.01.2021 and shall be valid for a period of one (1) year. Either party may terminate this MOU by giving thirty (30) days' notice in writing to the other.
- 5.2 Neither NATCO nor BCOP shall discriminate on the basis of race, religion, creed, color, sex, nationality, age, marital status, public assistance status, in relation to this MOU.
- 5.3 Neither NATCO nor BCOP shall be responsible for any delays or failure to perform any obligation under this MOU due to causes beyond the reasonable control of such party. Notwithstanding the foregoing, NATCO


SECRETARY
BAPATLA EDUCATION SOCIETY
BAPATLA





and BCOP agree to cooperate in good faith to mitigate the effect of any such delays or failures to perform, with the goal of achieving, to the extent possible, the objectives of this MOU.

- 5.4 Nothing in this MOU is intended or should be construed as creating the relationship of co-partners, joint ventures, or an association among the parties, nor shall any party, its employees, agents, students or representatives be considered employees, agents or representatives or any party to this MOU.
- 5.5 It is specifically agreed that neither party shall be responsible for costs or expenditures incurred by the other in the conduct of the programs / project contemplated hereby.
- 5.6 This MOU shall be governed by the laws of India and the courts at Hyderabad having the exclusive jurisdiction over others.
- 5.7 All amendments to this MOU must be in writing and executed by an authorized representative of each of the parties.

IN WITNESS WHEREOF the Parties have caused this MOU to be signed by their duly authorized representatives on the day first written above.

For Natco Pharma Limited



A handwritten signature in blue ink.

Mr. Lakshminarayana. A
Vice President (HR & OD)

For BAPATLA EDUCATION SOCIETY

A handwritten signature in blue ink.

SECRETARY
SECRETARY
BAPATLA EDUCATION SOCIETY
BAPATLA

Inhalation Drug Delivery Systems

Dr. V. Satyanarayana* and Dr.T.E.Gopala Krishna Murthy

** DGM, Natco Pharma Pvt LTD- Hyderabad*

Introduction (1-5)

Since thousands of years ago, humans have been given pharmacologically



Bapatla College of Pharmacy

PATRONIZED BY

BAPATLA EDUCATION SOCIETY



IMPACT LECTURE SERIES

Sponsored by

INSTITUTION'S INNOVATION COUNCIL



**INSTITUTION'S
INNOVATION
COUNCIL**
(Ministry of HRD Initiative)

Series - II Online Session

26-July - 2022



**Ministry of Education's
INNOVATION CELL**
(GOVERNMENT OF INDIA)

Resource Persons



Dr. Chittineni Aruna

**Professor - Department of CSE,
KKR & KSR Institute of Technology and Sciences,
Vinjanampadu, Guntur, Andhra Pradesh
Co ordinator- MSME
President – KITS-IIC & Convener- EISC**



Dr. Ravi Sankar Kothamasu

**Assistant General Manager
Intellectual property rights
NATCO PHARMA LIMITED**

**Lecture - I
Innovation skills for future
11.00.a.m. - 12.00.p.m.**

**Lecture - II
Impact of IPR on
Pharmaceutical industry
12.00.p.m. - 1.00p.m.**

Organized by

Dr. V. Sai Kishore

President - IIC - BCOP

Dr. T.E. Gopala Krishna Murthy

Principal